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ABSTRACT 
 
The prostate is an androgen-dependent male reproductive organ that is 
comprised of epithelial and stromal compartments.  The epithelial compartment 
contains basal, luminal, and neuroendocrine cells.  Two types of prostate 
epithelial stem cells (P-SCs), basal stem cells and luminal stem cells, have been 
identified in both human and mouse adult prostates based on tissue 
recombination models, cell lineage tracing, and in vitro prostasphere or organoid 
cultures.  Using lineage-tracing with P63CreERT2 and prostasphere culture, we 
show here that the sphere-forming P-SCs are P63-expressing cells and reside in 
the basal compartment.  Therefore we designate them as basal P-SCs (P-
bSCs).  P-bSCs are capable of differentiating into AR+ and CK18+ organoid 
cells, but not vice versa.  We also report that prostaspheres contain quiescent 
stem cells, which possess more potent self-renewal capacity. Distinct from other 
tissue stem cells, P-bSCs do not contain Lgr5+ cells. 
The fibroblast growth factor signaling axis regulates embryonic stem cell 
development as well as tissue specific stem cell maintenance and differentiation.  
However, the role of FGF signaling in P-SC self-renewal and differentiation is 
still elusive.   We show that the type 2 FGF receptor (FGFR2) signaling axis is 
crucial for preserving self-renewal and preventing the differentiation of P-bSCs.  
FGFR2 signaling mediated by FGFR substrate 2α (FRS2α) is indispensable for 
formation and maintenance of prostaspheres derived from P63+ P-bSCs. 
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Ablation of Fgfr2 in vivo reduces P63-expressing basal cells, and promotes 
basal-to-luminal differentiation.  In addition, ablation of Fgfr2 in P63+ cells 
disrupts postnatal development of the prostate. 
Accumulating evidence has also shown that prostate cancer (PCa) progression 
is frequently associated with dysregulation of FGF signaling. Herein, we report 
that forced expression of FGF9 in prostate epithelial cells leads to high grade 
prostatic intraepithelial neoplasia (PIN).  Overexpression of FGF9 in TRAMP 
mice induces more malignant PCa and higher frequency of metastasis. 
Hyperproliferative stromal cells are shown in the F9TG and F9TRAMP mouse 
prostates.  Reactive stroma which upregulates TGF-β1, was observed in F9TG 
and F9TRAMP prostates. We also show that transcription factor c-Jun is a 
mediator in the FGF9-TGFβ1 axis.    
Collectively, our study provides new insights into prostate stem cells and 
prostate cancer. Upset of the intricate balance of FGF signaling in the prostate 
disrupts stem cell homeostastasis and prostate development, and initiates 
prostate tumorigenesis. 
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CHAPTER I 
INTRODUCTION 
 
The prostate is a compound tubuloalveolar exocrine gland of the male 
reproductive system whose secretion constitutes roughly 30% of the volume of 
the semen. The human male prostate surrounds the urethra below the urinary 
bladder. Human prostate is an acorn-shaped organ that can be divided into 
three histologically distinct regions: the peripheral zone (PZ), central zone (CZ), 
and transition zone (TZ)(1) . Around 70-80% of prostatic cancers originate from 
the peripheral zone, while benign prostatic hyperplasia (BPH) occurs mainly in 
the transition zone (2,3). Unlike the human prostate, the mouse prostate 
consists of four different pairs of lobes, designated as the anterior lobes (AP), 
dorsal lobes (DP), lateral lobes (LP), and ventral lobes (VP). The dorsal and 
lateral lobes are frequently referred to the dorsolateral lobes (DLP). These lobes 
are arranged circumferentially around the urethra (4). 
In spite of the anatomical distinctions, both the human and mouse prostates 
exhibit similar glandular morphology and are composed of epithelial and stromal 
compartments separated by basement membranes. Both the human and mouse 
prostates contain three epithelial cell types.  The majority of the epithelial cells is 
luminal cells, which are column-shaped secretory cells. Between the luminal 
cells and the underlying basement membrane are spindle-shaped basal cells 
and rare neuroendocrine cells with unidentified function. The luminal cells are 
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characterized by expression of the androgen receptor (AR), cytokeratin 8 and 
18, Nkx3.1, and prostate specific antigen (PSA) in human prostates. Basal cells 
are characterized by the expression of p63, cytokeratin 5, and cytokeratin 14.  
Neuroendocrine cells can be specified by the expression of synaptophysin and 
chromogranin A. 
The histological difference between human and mouse prostates lies in the 
stromal cell density. In mouse prostates, stromal cells have almost the same cell 
number as epithelial cells, while in human prostates, stromal to epithelial cell 
ratio is around 5:1.  Both the mouse and the human prostate stroma is largely 
composed of smooth muscle cells (SMC), fibroblasts, extracellular matrix, blood 
vessels, nerves, and immune cells. The SMC cells, which express α-smooth 
muscle actin, tightly adheres to basement membrane and surround the luminal 
epithelial cells. Adult prostate stroma normally consists mainly of smooth muscle 
cells. SMC cells number is considerably reduced and replaced by fibroblasts and 
become less differentiated during progression to malignancy (5). The fibroblast 
and other stromal cells are loosely associated with epithelial cells and dispersed 
within the stromal matrix. During wound healing and in the reactive stroma, both 
SMC and fibroblast undergo extensive phenotypical switch, which will be 
discussed in Chapter IV. 
The mouse prostate development starts at embryonic day 17 (E17) when the 
urogenital sinus epithelial cells (UGE) grow into surrounding urogenital sinus 
mesenchyme (UGM) in anterior, ventral, dorsal, and lateral directions, which 
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subsequently form the four prostate lobes, respectively. This process requires 
interactions between UGE and UGM. Androgen receptor (AR) positive cells in 
the stroma regulate epithelial cell growth, death and differentiation via stroma-
produced “andromedins”, which includes fibroblast growth factor (FGF), insulin-
like growth factor (IGF), epidermal growth factor (EGF), Wnt and hepatocyte 
growth factor (HGF). In the classic in vivo recombination assay, isolated single 
epithelial cells are combined with rat UGM and grafted under the renal capsule. 
UGM is informative in directing the growth and differentiation of epithelial cells. 
Prostate development and tissue homeostasis are both finely regulated process. 
It is believed that stem cells sit at the top of the lineage hierarchy of the cellular 
organization. Stem cells contribute to all cell lineages of the prostate and 
maintain homeostasis. Evidence also supports the hypothesis that prostate 
cancer arises from malignant transformation of stem cells. Stem cells acquire 
epigenetic modifications and genetic mutations through exposure to insults, 
resulting in the dysregulation of normal stem cell functions and even worse 
outcome: cancer (6,7). Therefore, to understand the cellular composition of the 
prostate stem cells provide insights into the cells of origin for cancer. To identify 
the signaling pathways that regulate stem cell functions may lead to effective 
therapies for prostate cancer treatment. 
Prostate cancer is the most common cancer in American men other than skin 
cancer, and second leading cause of cancer death only after lung cancer. The 
American Cancer Society’s estimates for prostate cancer in the United States for 
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2015 are about 220,800 new cases of prostate cancer and 27,540 deaths from 
prostate cancer. About 1 man in 7 will be diagnosed with prostate cancer during 
his lifetime, and around 1 man in 38 will die of prostate cancer. 
As described, there are three histologically distinct regions in the human 
prostate: the peripheral zone (PZ), central zone (CZ), and transition zone (TZ). 
Benign prostatic hyperplasia (BPH), a non-cancerous overgrowth in aging men, 
occurs mainly in the transition zone, while prostate cancer arises primarily in the 
peripheral zone. >95% of prostate cancers are classified pathologically as 
adenocarcinoma, while the other rare types include sarcomas, small cell 
carcinomas, neuroendocrine tumors (other than small cell carcinomas), and 
transitional cell carcinomas. 
Histopathological studies of prostate cancer tissue have suggested that prostate 
cancer starts out as a pre-cancerous condition, although this is not certain yet. 
Two types of pre-malignant lesions were shown, proliferative inflammatory 
atrophy (PIA), and prostatic intraepithelial neoplasia (PIN). PIA belongs to the 
atrophic lesions that is common in the prostate. It has been shown that the 
location of PIA in the periphery of the gland is close to prostate carcinoma, and 
is capable of directly transforming to malignant or pre-malignant epithelia (8). 
PIN is recognized as a continuum between low-grade (LGPIN) and high-grade 
(HGPIN) form. While HGPIN is considered to be precancerous lesions of the 
prostate, most cases of LGPIN do not progress, thus it has different clinical 
outcomes than does HGPIN. HGPIN is generally characterized by the 
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appearance of luminal epithelial hyperplasia, reduction in basal cells, 
enlargement of nuclei, cytoplasmic hyperchromasia, and nuclear atypia. HGPIN 
is thought to represent the immediate precursor of early invasive 
adenocarcinoma, which can be classified into four architectural patterns: tufting, 
micropapillary, cribriform, and flat.  
The progression of PCa is a multiple-step process of orderly events, complicated 
by its heterogeneity and driven by various genetic abnormalities.  PCa almost 
invariably metastasizes to the bone, which accounts for most of the morbidity 
and mortality of PCa patients (9).  At early stages, PCa is androgen responsive; 
androgen deprivation is a common treatment that generally causes PCa to 
regress.  However, most PCa eventually recurs, becomes castration-resistant, 
and eventually develops metastases (10). 
A number of tumor suppressor genes and proto-oncogenes are involved in the 
development and progression of PCa (10), such as NKX3.1, PTEN, MYC, 
NOTCH-1. In approximately 40% of the primary prostate tumors, a recurrent 
translocation of an ETS transcription factor ERG to the TMPRSS2 promoter 
region occur, which results in constitutively active from of the TMPRSS2-ERG 
fusion protein (11-13). 
A series of genetically engineered mouse models have been generated to 
recapitulate the pathological and physiologic characteristics of human PCa (14). 
Viral oncogene driven model, TRAMP (transgenic adenocarcinoma of mouse 
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prostate) model, is a transgenic line contains a minimal probasin promoter that 
express SV40 large T and small t tumor antigens, both of which serve as 
oncoproteins(15)(15). The TRAMP mice characteristically develop distinct high-
grade PIN and/or PCa in the epithelium by 10 weeks of age. Distant site 
metastases are readily detectable as early as 12 weeks of age, primarily to the 
lungs, liver and lymph nodes and less often to bone, kidneys and adrenal gland.  
Androgen-depletion by castration doesn't delay the overall progression to poorly 
differentiated and metastatic disease (16-18). Although this model exhibits 
neuroendocrine phenotype at late stages, it is still a useful model in studying 
metastatic spread. Moreover, neuroendocrine phenotype is emerging to be 
important in the prognosis, evolution and progression of castration-resistant 
human prostate cancer. 
PTEN is a second generation of PCa model which has used loss-of-function 
mutations in PTEN (phosphatase and tensin homolog deleted from chromosome 
10). PTEN is a negative regulator of AKT, and most oncogenic phenotypes of 
PTEN loss are attributed to AKT activation (19,20). In human, PTEN deletions 
and/or mutations are found in 30% of primary prostate cancers and 63% of 
metastatic prostate cancers.  
Aside from the genetic or epigenetic modifications in prostate epithelial cells, 
stromal cells are equally critical in tumorigenesis. A stromal reaction in cancers 
seems similar, if not identical, to a generic wound repair response. In the wake 
of reactive stroma, extracellular matrix production deposition is elevated, and 
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growth factors and matrix remodeling enzymes are overwhelmed to create a 
growth-promoting microenvironment. Meanwhile, stimulated angiogenesis and 
influx of tumor associated macrophages (TAM) enhance tumor progression (21). 
Given the magnitude of stromal changes are related to tumor aggressiveness 
and patient outcome, the tumor stroma has emerged to be a valid target for 
therapy. Stroma factors has gradually been used a prognostic and treatment 
predictive markers, in conjunction with other conventional epithelial cell markers. 
New clinical diagnosis and treatment for prostate cancer is on the rise. Prostate-
specific antigen, or PSA, is a protein produced by cells of the prostate gland. 
The PSA test has been widely used to screen men for prostate cancer, in 
conjunction with urine test to look at the level of prostate cancer antigen 3 or an 
TMPRSS2:ERG after a digital rectal exam (DRE). Prostate cancer therapy 
includes radical prostatectomy, radiation therapy, hormonal therapy, and 
immunotherapy. Since prostate cancer is largely dependent on androgen 
receptor signaling in its early development, targeting androgen receptor (AR) 
axis signaling or to lower testosterone levels is the first-line therapy for prostate 
cancer. There are different types of drugs on the market: (1) Luteinising 
hormone (LH) blockers, (2) Gonadotrophin releasing hormone (GnRH) blockers, 
(3) Anti androgens (4) Abiraterone (Zytiga) and Enzalutamide (Xtandi). A more 
potent AR inhibitor, ARN-509 (Aragon) is in clinical trial and is purportedly more 
efficacious than enzalutamide. However, the androgen therapy is palliative, as 
recurrence of the tumor is almost inevitable at some time after the androgen 
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therapy. The recurrent tumors are then generally androgen independent and 
highly malignant. Unfortunately, so far, there are still no effective drugs for 
recurring prostate cancer. The only cell-based cancer immunotherapy currently 
approved for treatment of prostate cancer is Dendreon’s Provenge. FGFR 
inhibitors have also shown encouraging clinical outcomes in prostate cancer, 
however, some challenges of FGFR inhibitor development remain, for example, 
FGFR-mediated recurrence or resistance. Thus, new drug discovery is in urgent 
need.  
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CHAPTER II 
PROSTASPHERE-FORMING STEM CELLS ARE DERIVED FROM THE P63-
EXPRESSING BASAL COMPARTMENT 
 
Introduction 
The prostate is an androgen-dependent organ.  Androgen-deprivation results in 
massive apoptosis of the epithelial cells and prostate atrophy. During the 
regressed state, 90% of the luminal cells undergo apoptosis while most of the 
basal cells survive. However after androgen replenishment, the surviving 
epithelial cells actively proliferate and the prostate regenerates back to the 
normal size in 14 days. This regression/regeneration cycle can be repeated for 
at least 15 rounds, providing the first clue that there is a type of castration 
resistant prostate stem cells that contribute to prostate regeneration (22-24). It 
has been suggested that prostate stem cells may reside in the proximal region of 
the mouse prostate (25,26). Prostate stem cells are slow cycling cells which are 
capable of existing its dormancy and reentering cell cycle in vitro. Together with 
urogenital mesenchyme, prostate stem cells have the ability to reconstitute 
prostate structures in renal capsule. 
Emerging evidence indicate that P-SCs reside in both basal and luminal cell 
compartments of the human and mouse prostate under different circumstances. 
In vitro sphere/organoid culture, in vivo renal capsule implantation, FACS 
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analysis, and in vivo lineage tracing assays have shown that basal stem cells 
have self-renewal and multi-lineage differentiation capacities (27-33). 
Specifically, CK5, CK14-positive basal cells have been shown to give rise to 
basal, luminal and neuroendocrine cells during postnatal development (32). On 
the other hand, a subtype of luminal cells that express Nkx3.1 during castration 
can give rise to both basal and luminal cells both in in vitro organoid culture and 
in vivo (34,35). However, other studies also imply that during tissue homeostasis 
and regression/regeneration, both basal stem cells and luminal stem cells are 
mostly self-sustained (36,37). Interestingly, it has been reported that in 
developing prostatic epithelia, basal cells display both symmetric and 
asymmetric divisions leading to different cell fates, while luminal cells only 
exhibit symmetrical divisions (33).  Although the hierarchy of P-SCs in basal (P-
bSCs) and luminal (P-lSCs) compartments and their relative importance in 
prostate biology and pathology are still not fully certain, both lineages of cells 
have been shown capable of, although with different plasticity, developing 
prostate cancers with distinct aggressiveness and molecular signatures upon 
loss of Pten function (15,36,38-40). 
Prostasphere cell cultures have been extensively used for in vitro P-SCs 
propagation.  Prostasphere cells express basal cell cytokeratins and P63, and 
are capable of self-renewal and multi-lineage differentiation.  However, the cell 
lineage of prostaspheres is not clear.  Moreover, whether the prostasphere 
forming cells represent P-SCs is still controversial.  In vitro growth of luminal-
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resident P-SCs remained problematic until two groups developed distinct culture 
systems recently (34,41).    One group shows that both CARNs and normal 
prostate luminal epithelial cells can form prostate organoids and exhibit 
functional androgen receptor (AR) activity in culture.  The other group shows 
that a 3D culture system supports expansion of primary mouse and human 
prostate organoids, which are composed of fully differentiated CK5+ basal and 
CK8+ luminal cells and preserve androgen responsiveness.  Although both 
basal and luminal cells give rise to organoids, luminal cells-derived organoids 
more closely resemble prostate glands (41). 
Herein we report that prostaspheres were derived from P63-expressing basal 
cells.  The cells were designated as basal prostate stem cells (P-bSCs) to be 
distinguished from luminal P-SCs (P-lSCs).  In addition, prostaspheres were 
capable of forming organoids with functional differentiation markers AR and 
CK18.  However, organoids-derived cells could not form prostaspheres.  The 
results suggest that P-bSCs represent more primitive P-SCs than P-lSCs.  We 
also showed that both the prostate and prostaspheres had a reservoir of 
quiescent stem cells, which possessed a high self-renewal capacity.  Different 
from other rapid-turnover organs and cells, the prostate and prostaspheres did 
not contain Lgr5+ cells.   
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Materials and Methods 
Animals     
Mice were housed under the Program of Animal Resources of the Institute of 
Biosciences and Technology, Texas A&M Health Science Center in accordance 
with the principles and procedure of the Guide for the Care and Use of 
Laboratory Animals.  All animal procedures were approved by the Institutional 
Animal Care and Use Committee.  Mice carrying the Nkx3.1cre, P63CreERT2, 
K5H2B/GFP, Lgr5EGFP-CreERT2, and ROSA26LacZ reporter alleles were bred and 
genotyped as previously described (42-46).  Prostates were harvested 
immediately after the animals were euthanized by CO2 asphyxiation. 
For inducible gene activation, mice bearing P63CreERT2 and the reporter alleles, 
as well as their wildtype littermates were i.p. injected of 20 mg/ml tamoxifen 
(Sigma; diluted in corn oil) at a dosage of 100 mg/kg.  For in vitro ablation, the 
cells were treated with 5 mM 4-hydroxytamoxifen (Sigma, in ethanol) at a final 
concentration of 500 nM. 
Prostaspheres and organoid cultures     
The conditions for preparing, culturing, and passaging prostate spheres were 
developed based on published protocols (29).  Prostates were dissected from 6- 
to 8-week-old male mice immediately after euthanasia, minced with a pair of 
steel scissors.  The minced tissues were then incubated with 10 ml DMEM with 
10% FBS containing 1 mg/ml collagenase (Sigma) at 37°C for 90 minutes.  The 
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cells were then washed with PBS, and incubated with 0.25% trypsin/EDTA for 
10 minutes at 37°C, followed by passing through a 25-gauge syringe several 
times.  After adding FBS to the cell suspension to inactivate trypsin, the cells 
were passed through a 40-μm cell strainer, washed with DPBS (Sigma), and 
counted.  Prostate cells were suspended with 50 μl of the prostate epithelial 
growth medium (PrEGM, Lonza, Walersville) at a density of 6x105/ml and then 
mixed with Matrigel (BD Biosciences) at a ratio of 1:1.  The mixtures (100 µl) 
were plated around the rim of wells in a 12-well plate.  After incubation at 37°C 
for 30 minutes or until the Matrigel solidified, 1 ml of PrEGM was added to each 
well, and the plates were transferred to a 5% CO2 tissue culture incubator.  The 
cells were then cultured at 37°C for 8-10 days with the medium replenished 
every other day, until the spheres reached the size over 60 μm in diameters.  
The Matrigel was then digested by incubation in 1 ml of 1 mg/ml dispase solution 
(Life Technologies, Grand Island, NY) at 37°C for 30 minutes.  The spheres 
were harvested for analyses or subcultures by centrifugation.  For subculturing, 
the pellets were digested with 1 ml of 0.05% trypsin/EDTA (Invitrogen) for 5 
minutes at 37°C, followed by inactivation of trypsin by FBS. The cells were 
passed through a 40-μm cell strainer, counted, and replated. 
For organoid culture in hepatocyte medium as described (34),  the cells were 
resuspended in hepatocyte culture medium (designated as Medium H), 
consisting of: hepatocyte medium supplemented with 10 ng/ml EGF (Peprotech), 
10 µm Fasudil (Tocris), 1X Glutamax (Gibco), 5% Matrigel (Corning), and 5% 
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charcoal-stripped FBS (Gibco) that had been heat-inactivated at 55oC for 1 hour.   
10,000 dissociated cells were resuspended in Medium H and plated in ultralow-
attachment 96-well plates (Corning) in the presence of 100 nM DHT.  100 µl of 
fresh Medium H was added to the wells every other day.  The cells were 
incubated at a 37oC for 8-10 days.  The organoids were dissociated for 
subcultures by incubation in trypsin/EDTA with the addition of 10 µM Fasudil for 
5 minutes at 37oC. 
For organoid culture in the DMEM/F12 medium (41), prostate cells (3x104) 
isolated as above were suspended in 50 µl of the DMEM/F12 medium 
(designated as Medium DF), which was supplemented 1X B27 (Life 
technologies), 10 mM HEPES, Glutamax (Life technologies), 
Penicillin/Streptomycin, 10 ng/ml EGF, 500 ng/ml recombinant R-spondin1, and 
100 ng/ml recombinant Noggin (Peprotech), the TGF-β/Alk inhibitor A83-01 
(Tocris), and 1 nM dihydrotestosterone (Sigma).  The cell suspension was mixed 
with Matrigel (1:1) and plated around the rim of the wells in a 12-well plate.  After 
incubation at 37oC for 30 minutes for solidification, 1 ml of Medium DF was 
added to each well.  The cells were incubated at 37oC for 8-10 days with a half 
of the medium was replenished every other day. The organoids were dissociated 
for passaging by trypsinization with trypsin/EDTA with the addition of 10 µM 
Fasudil for 5 minutes at 37oC. 
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BrdU labeling     
For BrdU incorporation assay, BrdU (Sigma Co, Saint Louis, MO) was added to 
the culture medium at a final concentration of 2.5 µM.  After incubation at 37°C 
for 40 hours, the spheres were harvested as described and BrdU positive cells 
were identified by immunostaining.  For long-term BrdU retention, 24 hours after 
labeling, the medium was aspirated and the culture were washed 3 times with 
fresh medium to remove free BrdU.  The cells were cultured in fresh medium for 
another 7 days prior to being harvested for analyses.  Immunostaining with anti-
BrdU antibody (1:500 dilution; Sigma Co, Saint Louis, MO) was used to detect 
BrdU labeled cells. 
Flow cytometry and cell sorting     
Dissociated single prostate cells were incubated with FITC-conjugated anti 
CD31, CD45, Ter119 antibodies, and PE-conjugated anti-Sca-1 antibody 
(eBioscience), or Alexa 647-conjugated anti CD49f antibody (Biolegend) diluted 
in the cell sorting buffer (2% FBS in PBS).  Primary antibody labeling was 
conducted by incubation for 20 minutes in ice-cold conditions with antibody 
dilution according to manufacturer’s suggestions in a volume of 100 µl per 105-
108 cells.  The cells were then washed in 1 ml ice-cold cell sorting buffer to 
remove unbound antibodies, resuspended in 0.5 ml cell sorting buffer, followed 
by resuspension in the cell sorting buffer for fluorescence-activated cell sorting 
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on a BD FACSAria I SORP.  The sorted cells were collected in DMEM medium 
containing 20% FBS. 
Histology     
Prostaspheres or cells were fixed with 4% paraformaldehyde-PBS solution for 
30 minutes at room temperature.  The spheres were pelleted and suspended in 
Histogel.  After solidifying at room temperature, the pellets were ethanol 
dehydrated, paraffin embedded in paraffin, and sectioned at 5 µm thickness as 
described (29).  For histology analyses, sections were re-hydrated for H&E 
staining.  For immunostaining, the slides were incubated in boiling citrate buffer 
(pH 8.0) for 20 minutes for antigen retrieval.  The source and concentration of 
primary antibodies are: anti-cytokeratin 8 (1:15 dilution) and anti-cytokeratin 5 
(1:500 dilution) from Fitzgerald Industries International (Concord, MA); anti-
cytokeratin 18 (1:200 dilution) and anti-androgen receptor (1:200 dilution) from 
Abcam; mouse anti-BrdU (1:500 dilution) from Sigma (St Louis, MO); mouse 
anti-cytokeratin 14 (1:100 dilution) and anti-p63 (1:150 dilution) from Santa Cruz 
(Santa Cruz, CA), rabbit anti-β-Catenin (1:200 dilution), and anti-cleaved-
Caspase 3 (1:200 dilution) from Cell Signaling Technology.  After washing, the 
specifically bound antibodies were detected with and fluorescence-conjugated 
secondary antibodies (Invitrogen) or the ExtraAvidin Peroxidase System 
(Sigma).  For the immunofluorescence staining, the nuclei were counter stained 
with To-Pro 3 before being observed under a confocal microscope (Zeiss LSM 
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510).  For LacZ staining, the prostates or prostaspheres were lightly fixed with 
0.2% glutaraldehyde for 1 hour at room temperature, and then incubated 
overnight with 1 mg/ml X-Gal at room temperature. After washing with PBS, the 
tissues or prostaspheres were post-fixed with 4% PFA for 1 h, ethanol 
dehydrated, paraffin-embedded, and sectioned for subsequent analyses. 
Western blotting     
The prostate spheres were pelleted by centrifugation, resuspended in  RIPA 
buffer (50 mM Tris-HCl buffer pH 7.4, 1% NP40, 150 mM NaCl, 0.25% Na-
deoxycholate, 1 mM EGTA, 1 mM PMSF), and homogenized with a tissue 
homogenizer.  The protein extracts were harvested by centrifugation.  Samples 
containing 30 μg proteins were separated by SDS-PAGE and electroblotted onto 
PVDF membranes.  The membranes were then incubated with the indicated 
antibodies at 4°C overnight.  The dilutions and the sources of the antibodies are: 
anti-phosphorylated ERK1/2, 1:1000; anti-phosphorylated AKT, 1:1000; anti-
ERK1/2, 1:1000; and anti-AKT, 1:1000 (Cell Signaling Technology).  After being 
washed with the TBST buffer for three times to remove nonspecific antibodies, 
the membranes were then incubated with the horseradish peroxidase 
conjugated secondary antibody at room temperature for 1 hour, followed by 
washed with the TBST buffer for three times to remove the unbound antibodies.  
The specifically bound antibodies were visualized by using the ECL-Plus 
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chemoluminescent reagents. The films were scanned with a densitometer for 
quantitation. 
RNA expression    
 Total RNA was isolated from prostaspheres using TRIzol RNA isolation 
reagents (Life Technologies).  The SuperScript III reverse transcriptase 
(Invitrogen, Carlsbad, CA) and random primers were used for first-strand cDNAs 
synthesis according to manufacturer’s protocols. Real-time PCR analyses were 
carried out using the Fast SYBR Green Master Mix (Life Technologies).  After 
normalization to the β-actin internal control, the relative abundance of mRNA 
was calculated using the comparative threshold (CT) cycle method.  The mean ± 
sd from at least three individual experiments are shown. 
Statistical analysis     
Statistical analysis was performed using the two tailed t test, with significance 
set to P<0.05.  Error bars indicate standard deviation. 
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Results 
Prostaspheres originate from basal epithelial cells and maintain basal cell 
properties 
To establish prostasphere cultures, single cell suspensions were prepared from 
adult prostate tissues and plated in Matrigel as described (29).  The spheres 
follow a step-wise development. Small, solid spheres were visible at day 5 and 
two-layer spheres around day 7 to 10, which reached an average size of 100 μm 
or larger in diameter.  The outermost layer of the spheres and the layers closely 
underneath were aligned concentrically around a central cavity filled with 
acellular substances (Fig. 2.1A). During development, the NKX3.1 homeobox 
protein is the earliest known marker for prostate epithelial precursor cells and 
prostate formation (47).  Cell-lineage tracing with the Nkx3.1cre-activated 
ROSA26LacZ reporter demonstrated that cells in prostaspheres were of epithelial 
origin as illustrated by LacZ staining (Fig. 2.1B). 
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Fig. 2. 1. Prostaspheres are derived from basal cells and maintain basal cell 
properties.   
A. Phase contrast image of representative prostaspheres in Matrigel (a) and H&E 
staining of a prostasphere section (b).  B.  X-gal staining of prostaspheres derived from 
the indicated mouse genotype.  C.  Immunostaining of prostaspheres with luminal cell-
specific CK8 and basal cell-specific CK5.  D.   Disassociated prostasphere cells were 
cultured on tissue culture dishes for 3 days and stained with anit-CK14 or CK8 
antibodies as indicated.  E&F.  FACS analysis of the primary and 1st generation 
prostaspheres.  Numbers indicate percentages of indicated cell type (E).  Real-time RT-
PCR analyses of CK14 and CK18 expression in primary prostate cell suspensions (P0) 
and P1 or P8 prostaspheres (F).  f, floxed; w, wildtype; CK5, cytokeratin 5; CK8, 
cytokeratin 8; CK14, cytokeratin 14; TP3, To-Pro3; *, P≤0.05. 
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Most cells in the spheres expressed basal cell-specific cytokeratin (CK) 5; only a 
few cells in the inner layers expressed luminal cell-specific CK8 (Fig. 2.1C).  
However, when the cells were transferred to regular 2-D culture conditions, a 
higher number of cells displayed luminal keratin (CK8+) (Fig. 2.1D).  FACS 
analysis revealed that in contrast to 28% Sca-1+/CD49f+ cells in primary 
prostates, 74% of the sphere cells were Sca-1+/CD49f+, indicating that the 
sphere culture enriched cells with basal cell properties (Fig. 2.1E).  Real time 
RT-PCR analysis also showed an 80-fold increase of CK14 expression in the 1st 
and 8th generation of spheres and a significant reduction of CK18 expression in 
the 8th generation sphere (Fig. 2.1F). 
 
Prostaspheres are derived from P63-expressing basal stem cells 
Even though prostaspheres were derived from the Nkx3.1-expressing progenitor 
cells, expression of Nkx3.1 in prostaspheres was below the detection limit of RT-
PCR (Fig. 2.2A).  Since Nkx3.1 is expressed in luminal epithelial cells of adult 
prostates (48), the data indicate that prostaspheres do not contain or only 
contain scanty terminal differentiated luminal epithelial cells, which is consistent 
with the rare CK8 staining in the prostaspheres (Fig. 2.1C). 
P63 is expressed in prostate basal cells and is required for prostate 
development. P63-/- mice fail to form prostate (49-51). Lineage tracing with the 
ROSA26LacZ reporter activated by P63CreERT2 at 2 weeks after birth showed that 
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LacZ positive progeny were distributed in both basal and luminal compartments 
(Fig. 2.2Ba). This indicated that P63-expressing cells gave rise to both luminal 
and basal cells as reported (52).  To determine whether prostaspheres were 
derived from P63 expressing basal cells, the prostaspheres derived from 
P63CreERT2 -ROSA26LacZ mice were treated with 4-hydroxytamoxifen (4-OHT) at 
day 1 to activate the ROSA26LacZ reporter.  X-Gal staining revealed that almost 
all prostaspheres were homogeneously LacZ+ (Fig. 2.2Bb,c).  Thus, the spheres 
were derived from P63-expressing basal stem cells. Immunofluorescence 
revealed that Ki67 was co-localized with P63 and only located at the outermost 
layer of the spheres.  This indicated that most proliferating cells were P63-
expressing cells (Fig. 2.2C).  Sphere cultures of FACS-fractionated cells 
demonstrated that approximately 3.17% of basal cells formed spheres, while 
only 0.02% luminal and stromal cells formed spheres (Fig. 2.2D).  Together, the 
data indicated that prostaspheres contain basal cells but not terminally 
differentiated luminal cells.  And only basal cells, specifically P63-positive basal 
cells, have the highest capacity to self-renew in our culture system. The 
prostaspheres are derived from basal cells but not luminal cells, therefore the 
cells are designated as basal P-SCs (P-bSCs). 
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Fig. 2. 2. Prostaspheres are derived from P63-expressing basal cells. 
A. RT-PCR analyses of Nkx3.1 in primary (P0) and 1st generation prostaspheres (P1).  
B. X-Gal staining of prostate (a) or prostasphere (b,c) sections from the mice bearing 
ROSA26LacZ and P63CreERT2 reporter alleles.  Panel a, the mouse was injected i.p. with 
tamoxifen 2 weeks after birth and the prostates were harvested at 6 weeks..  Panels 
b&c, prostaspheres were treated with alcohol or 4-OHT at day 1 after the inoculation.  
C. Prostasphere sections were immunostained with anti-P63 and Ki67 antibodies.  D. 
Prostasphere forming assays for FACS fractionated cells.  P0, primary prostate cells; 
P1, 1st generation of prostaspheres; TP3, To-Pro 3 staining for nuclei; Ctrl, control; Bas, 
basal cells; Lum, luminal cells; Str: stromal Cells; *, P≤0.05. 
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The slow cycling cells in prostaspheres have high capacity to form 
prostaspheres 
One of the characteristics of stem cells is long-term label retaining. To determine 
the existence of label-retaining, namely slow-cycling, cells in the prostaspheres, 
BrdU was used to label and trace the cells engaged in DNA synthesis.  
Approximately 90% of cells in the outer layer displayed BrdU forty hours after 
labeling (Fig. 2.3Aa).  At seven days after labeling, a few BrdU+ cells in the outer 
layer were still visible.  This confirmed that the spheres contained rare long-term 
label retaining cells (Fig. 2.3Ab). 
To further determine whether these slow cycling or prostasphere-forming cells 
were basal cells, the tetracycline-regulated K5H2B/GFP reporter allele was used 
as described (53). Over 80% of prostaspheres derived from the reporter-bearing 
prostate were GFP+ in the absence of doxycycline (Fig. 2.3B), which further 
indicated that most of the prostaspheres were basal cells that expressed CK5.    
In contrast to the majority of GFP+ prostasphere cells in its absence, the 
presence of doxycycline resulted in only 1 or 2 GFP+ cells at the outer layer, 
which represented long-term label-retaining cells (Fig. 2.3Ca,b).  These long-
term label retaining GFP+ cells showed four-fold higher capacity to form spheres 
than GFP- cells (Fig. 2.3Cc). 
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Fig. 2. 3. Prostaspheres contain slow-cycling P-bSCs. 
A.  Prostaspheres were labeled with BrdU for 40 hours (a), or a 24-hour pulse and 7-
day chase (b). The labeled cells were detected by anti-BrdU immunostaining.  Arrow 
indicates label-retaining cells.  B. Merged images of phase contrast and fluorescent 
microscopy of prostaspheres bearing the K5H2B/GFP reporter showing GFP+ 
prostaspheres (a) are derived from K5 expressing basal cells and GFP- prostaspheres 
(b).  C.  FACS analyses of primary prostate cells from mice carrying the K5H2B/GFP 
reporter in the absence or presence of doxycycline (a&b).  Numbers indicate percent of 
GFP+ cells.  Insert, prostasphere derived from doxycycline treated K5H2B/GFP prostate.  
The FACS fractionated cells were cultured in Matrigel and the average sphere numbers 
derived from 100 cells were showed as mean ± sd (c).  D. The prostates bearing the 
K5H2B/GFP reporter allele with or without doxycycline were sectioned and GFP was 
detected by confocal microscopy (panels a&b), or subjected to FACS analyses (panels 
c&d).  The sphere forming activity of the 4 groups of cells was assessed and presented 
as numbers of spheres per 100 cells (e).  Dox, doxycycline; *, P≤0.05. 
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Consistently, in the absence of doxycycline, the majority of prostate basal cells 
in vivo were GFP+ (Fig. 2.3Da,c), which accounted for 15.5% of total prostate 
cells.  However, one month after feeding with doxycycline to repress GFP 
expression, only 5.3% of the cells in the prostate were still GFP+ (Fig. 2.3Db,d).  
Prostates with or without doxycycline treatment were then dissociated into single 
cells.  The GFP+ and GFP- cells were separated by cell sorting and cultured in 
Matrigel to assess their sphere-forming capacity.  The results showed that the 
GFP+ cells from the doxycycline treated group, which represented the long-term 
label retaining cells in the prostates, had a higher capacity in forming 
prostaspheres than the general population of basal cells (Fig. 2.3De).  None of 
the GFP- cells formed spheres with a diameter larger than 50 µm.  The results 
further demonstrate that label-retaining basal cells have a high capacity to form 
prostaspheres. 
 
P-bSCs have the capacity to form organoids, but not vice versa 
Two recent reports show that the luminal compartment contains P-SCs that form 
prostate-like organoids in two different in vitro conditions.  To determine whether 
the organoid-forming P-SCs and P-bSCs were interchangeable and shared the 
same properties, P-bSCs were transferred to the two organoid-culture 
conditions, namely Medium H and Medium DF as described in Methods.  
Interestingly, P-bSCs formed organoid-like structures with a morphology similar 
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to reported earlier in both media (Fig. 2.4Aa,b).  Immunostaining showed that 
the resulting organoids in Medium H contained cells expressing AR and luminal 
cell-specific CK18, but no longer P63 (Fig. 2.4Ac-e).  The organoids generated 
in Medium DF contained cells expressing AR and CK18.  Only a few cells 
located at the outer layer expressed P63 (Fig. 2.4Af-h).  Thus, the results 
indicate that prostaspheres contain organoid-forming cells, which can 
differentiate into luminal cells under the organoid culture conditions. 
To determine whether the organoids contained prostasphere-forming cells, 
primary prostate cells were first cultured in organoid conditions as reported.  The 
organoids cells were then harvested and grew either in the organoid or sphere 
culture conditions.  Although the cells continued to form organoids in the 
organoid culture conditions, none of them formed prostaspheres in the 
prostasphere culture condition (Fig. 2.4B).  Therefore, it was unlikely that the 
organoids contained prostasphere-forming P-bSCs.  Together with the data that 
prostasphere-forming P-bSCs were capable of forming organoids, the results 
indicate that P-bSCs sit in a higher hierarchy position than luminal resident 
organoid-forming P-SCs. 
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Fig. 2. 4. Prostasphere cells have the capacity to form prostate organoids, but not 
vice versa. 
A. Prostaspheres cultured in Matrigel with prostasphere culture medium (PrEGM) were 
dissociated and inoculated in organoid culture with hepatocyte (Medium H) or 
DMEM/F12 (Medium D/F) as described.  Panels a&b are phase contrast microscopy 
images.  Panels c-e and f-h are immunostaining of organoid sections from Medium H or 
Medium DF with the indicated antibodies.  B. Organoids cultured in the indicated 
medium were dissociated and inoculated in Matrigel-PrGEM.  Note that no organoid-
derived cells could form prostaspheres in PrEGM. 
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Neither the prostates nor the prostaspheres contain Lgr5-expressing cells 
Emerging evidence has indicated the coexistence of quiescent and active adult 
stem cells in mammals (54).  The leucine-rich repeat containing G-protein-
coupled receptor 5 (Lgr5) has been reported to be expressed in many active, but 
not quiescent, tissue stem cells (55,56).  To determine whether prostaspheres 
contained Lgr5+ cells, RT-PCR was employed to detect Lgr5 expression at the 
mRNA level in primary prostate cells and first generation prostaspheres.  The 
results showed that prostaspheres had no detectable Lgr5 expression although 
primary prostate cells exhibited a very low level of Lgr5 expression (Fig. 2.5A).  
In contrast, β-catenin expression was comparable between primary prostate 
cells and prostaspheres.  Consistently, no cells in prostaspheres derived from 
Lgr5EGFP-CreERT2/ROSA26LacZ mice were LacZ positive with or without 
administration of 4-OHT to activate CreERT2 (Fig. 2.5B).  This further confirmed 
there were no Lgr5 expressing cells in prostaspheres. Lineage tracing with 
Lgr5EGFP-CreERT2/ ROSA26LacZ reporter alleles in vivo failed to demonstrate 
progeny derived from Lgr5-expressing cells in the prostate (Fig. 2.5C).  
Combined with FACS analyses, RT-PCR data also showed that Lgr5 was only 
expressed in stromal cells, but not epithelial cells (Fig. 2.5D).  This indicate that 
unlike other active tissue SCs, active P-bSCs do not express Lgr5. 
 
 
30 
 
 
 
Fig. 2. 5. Lgr5 is not expressed in prostate epithelial cells and prostaspheres. 
A. RT-PCR analyses of the indicated genes in primary prostate cells (P0) and 1st 
generation prostaspheres (P1).  B. Prostaspheres derived from Lgr5EGFP/CreERT2;RosalacZ 
prostate were treated with 4-OHT treatment, wholemount stained with X-gal, and then 
sectioned.  C. Wholemount X-Gal staining of prostates and intestines from 
Lgr5EGFP/CreERT2;RosalacZ mice with or without tamoxifen administration. Noted that the 
blue LacZ staining is visible in intestine, but not in prostate.  D. RT-PCR analyses of 
Lgr4, Lgr5, and Lgr6 expression in primary prostate cells fractioned by FACS and 
prostaspheres.  β-actin was used as a loading control.  P0, primary prostate cells; P1, 
1st generation prostaspheres; M, molecular weight markers; B, basal cells; L, luminal 
cells; St, stromal cells; S, spheres derived from basal cells. 
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Discussion 
Prostasphere culture has been widely used for study and quantitation of self-
renewal activity of both human and mouse P-SCs (19,29,30).  However, the 
utility of this system has been questioned due to the fact that most of the cells in 
the prostaspheres are primarily CK5+ basal cells, but lack NKX3.1+ cells or their 
products. The two recent studies based on organoid culture shows that the 
resulting organoids differ significantly from prostate spheres, in that they retain 
both basal and luminal epithelia layers and preserve androgen-responsiveness. 
However, in our study, we for the first time demonstrated that P-bSCs were also 
capable of forming organoids.  In contrast, the organoid-forming cells were not 
able to form prostaspheres.  Therefore, the results reveal that P-bSCs represent 
stem cells in the prostate, which can give rise to both luminal and basal stem 
cells. The results indicate that the sphere culture system is a useful and reliable 
in vitro culture system to preserve prostate basal stem cell stemness.  
Adult stem cells are highly heterogeneous, including both quiescent stem cells 
and active stem cells. K5H2B/GFP has been used in various studies to identify 
quiescent stem cells across different tissues as hair follicles and mouse incisors. 
(53,57). Lgr5, which is an active stem cell marker, is expressed in a variety of 
intact tissues or during wound healing (55,56,58-60). In this study, we identified 
the slow-cycling quiescent stem cells by using both BrdU long-term dye retention 
and tracking in K5H2B/GFP mouse prostates and prsotaspheres that retained GFP 
over the long term. However, we were unable to detect Lgr5 positive cells in the 
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prostate and prostaspheres. This does not completely rule out the existence of 
active stem cells in the prostate and prostaspheres. It is possible that the 
prostate contains Lgr5+ cells after injury, like the liver and the pancreas, in which 
only injury causes the emergence of an Lgr5+ organoid-forming epithelial 
progenitor population. 
A recent novel barcoding technology by keeping track of cancer cells has 
provided insights into the presence of rare drug resistant pre-existing cancer cell 
populations that arise by selection in response to therapeutic challenge (61). 
This small population of cells that are drug resistant is very similar to cancer 
stem cells. Relapse of some malignancies has been attributed to emergence of 
cancer stem cells.  It has been reported that upon induction by loss of tumor 
suppressor genes, both P-bSCs and P-lSCs can be tumorigenic (15,40).  
Therefore, understanding how to manipulate these two types of P-SCs to 
undergo differentiation and remain silent will provide new avenues to retrain 
prostate cancer progression and relapse.  
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CHAPTER III 
TYPE 2 FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING IS 
REQUIRED FOR STEMNESS AND PREVENTS DIFFERENTIATION OF 
BASAL COMPARTMENT STEM CELLS 
 
Introduction 
The fibroblast growth factor (FGF) family consists of 22 genes encoding 
structurally related proteins, among them 18 are tyrosine kinase receptor binding 
ligands. Based on sequence homology, FGFs can be further divided into seven 
subfamilies: FGF1-2, FGF4-6, FGF3/7/10/22, FGF8/17/18, FGF9/16/20, 
FGF11/12/13/14, and FGF19/21/23. Among them, FGF11-14 are not 
transmembrane tyrosine kinase receptor binding ligands, and FGF19/21/23 are 
endocrine messengers which work systematically in the body. The remaining 
FGFs signal through autocrine or paracrine mechanisms locally in various 
tissues. FGF regulates a broad spectrum of biological activities by activating the 
transmembrane tyrosine kinases encoded by four highly homologous genes, 
denoted Fgfr1, Fgfr2, Fgfr3, and Fgfr4, in partnership with heparin sulfate 
proteoglycans or α-klotho or β-klotho. FGFRs consist of diverse splice variants 
that vary in both extracellular ligand-binding and the intracellular kinase domains 
(62,63). Activation of FGFRs triggers its autophosphorylation followed by FGFR 
substrate 2 (FRS2) phosphorylation that is associated with it and recruitment of 
phospholipase-Cγ (PLCγ) (64,65).  FRS2 has two isoforms, FRS2α and FRS2β. 
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FRS2α, which together with additional recruited adaptors and downstream 
signaling molecules, links multiple intracellular signaling pathways, including the 
mitogen-activated protein kinase/extracellular signal-regulated kinase 
(MAPK/ERK) and phosphinositide 3-kinase (PI3K)/AKT pathways (66,67). 
In the prostate, FGF ligands and receptors are partitioned between epithelial and 
mesenchymal compartments and mediate the communication between the two 
compartments, either directionally specific or reciprocally. Aberrant expression 
and activation of the FGF signaling axis is associated with many diseases 
ranging from developmental disorders and cancer, which will be discussed in 
Chapter IV (68).  Ablation of Fgfr2 in mouse prostatic epithelial precursor cells 
compromises bud formation, branching morphogenesis, growth, and acquisition 
of androgen-dependency of the prostate (45), whereas conditional ablation of 
Frs2α only impairs prostate branching morphogenesis and growth (69). 
The FGF signaling axis regulates a wide range of processes in embryonic 
development, stem cell maintenance, and differentiation.  FGF2 is required for 
sustaining self-renewal and pluripotency of human embryonic stem cells 
(hESCs) (70).  FGF4 stimulation of Erk1/2 is an autoinductive stimulus for 
pluripotent embryonic stem cells to exit self-renewal and commit to lineage 
differentiation (71). Precise regulation of Fgfr expression is required during 
hESC specification (72).  FGF signaling has also been implicated in a variety of 
tissue stem cell activities, including neural stem cells (73), bone marrow 
mesenchymal stem cells (74), and hematopoietic stem cells (75).  Studies from 
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our group have shown that the FGF signaling axis prevents differentiation of 
cardiac stem cells (76) and dental epithelial stem cells (77).  Disruption of FGF 
signaling leads to premature differentiation of cardiac progenitor cells.  However, 
thus far, the roles of FGF signaling in P-SC self-renewal and differentiation are 
still elusive.  It has been reported that paracrine stimulation of prostate 
basal/stem cells with FGF10 results in multifocal adenocarcinoma (78).  FGF7 
(KGF) has also been shown to suppress α2β1 integrin function and promotes 
differentiation of the transient amplifying population in human prostatic 
epithelium (79).  
Herein we report that FGF signaling mediated by FGFR2/FRS2α-dependent 
pathways plays a critical and specific role in self-renewal and differentiation of P-
bSCs.  Inhibition of FGF signaling impairs P-bSC self-renewal and induces its 
differentiation. Tissue specific ablation of Fgfr2 with the P63CreERT2 driver in 
prostaspheres or adult mice prostate reduces numbers of P-bSC. P63-positive 
basal cells are capable of giving rise to all epithelial lineages during prostate 
postnatal development (52). Conditional knockout of Fgfr2 in P63-positive basal 
cells in neonatal mouse prostate significantly compromises its postnatal 
development.  Our results indicate that FGFR2 in P63-expressing cells is critical 
for P-bSC self-renewal and differentiation both in vivo and in vitro and provides a 
novel avenue for control of P-bSC self-renewal by manipulation of FGF 
signaling. 
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Materials and Methods 
Animals    
Mice were housed under the Program of Animal Resources of the Institute of 
Biosciences and Technology in accordance with the principles and procedure of 
the Guide for the Care and Use of Laboratory Animals.  All experimental 
procedures were approved by the Institutional Animal Care and Use Committee.  
Mice carrying loxP-flanked Frs2, Fgfr1, Fgfr2 alleles, and the Nkx3.1cre and 
P63CreERT2 knock-in alleles were bred and genotyped as described (42-46).  
Prostate tissues were harvested for the described analyses after the animals 
were euthanized by CO2 suffocation. 
Inducible gene ablation    
For inducible gene ablation, mice bearing Fgfr1f/f P63CreERT2, Fgfr2f/f P63CreERT2, 
Fgfr1/2f/f P63CreERT2, and its wildtype counterpart alleles were administrated with 
tamoxifen (20 mg/ml stock solution in corn oil, Sigma) at 100 mg/kg.  For in vitro 
ablation, cells bearing the aforementioned alleles were treated with 4-
hydroxytamoxifen (Sigma, diluted in alcohol at a stock concentration of 5 mM) at 
the indicated concentrations. 
Prostasphere culture    
The conditions for culturing and passaging prostate spheres were adapted by 
modification of published procedures (29).  Briefly, prostates dissected from 6- to 
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8-week-old male mice were minced with a pair of steel scissors, followed by 
incubating with 1 mg/ml collagenase (Sigma) in 10 ml DMEM with 10% FBS at 
37°C for 90 minutes.  Cells were washed with PBS, further digested with 0.25% 
trypsin/EDTA for 10 minutes at 37°C, and passed several times through a 25-
gauge syringe.  After inactivation of trypsin by FBS, cells were passed through a 
40-μm cell strainer, washed with DPBS (Sigma) and counted.  Prostate cells 
(3x104) were suspended in 50 μl of the prostate epithelial growth medium 
(PrEGM) (Lonza, Walersville) and then mixed with Matrigel (BD Biosciences) at 
a ratio of 1:1.  The cell mixtures were plated around the rim of wells in a 12-well 
plate and allowed to solidify at 37°C for 30 minutes.  Then, 1 ml of PrEGM was 
added to each well, and the medium was replenished every other day.  After 
plating for 8-10 days, the spheres with a diameter over 60 μm were scored.  To 
harvest the spheres, the Matrigel was digested by incubation in 1 ml of 1 mg/ml 
dispase solution (Life Technologies, Grand Island, NY) at 37°C for 30 minutes, 
followed by centrifugation.  To subculture the spheres, the pellets were digested 
with 1 ml of 0.05% trypsin/EDTA (Invitrogen) for 5 minutes at 37°C.  After 
inactivation of trypsin by FBS, the cells were passed through a 40-μm filter, 
counted by a hemocytometer, and replated.  FGF7 or FGF10 was added to the 
cell culture medium at a final concentration of 10 ng/ml.  4-OHT was added to 
the cell culture medium at a final concentration of 500 nM. 
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Flow cytometry and cell sorting    
Dissociated single prostate cells were stained with FITC-conjugated anti CD31, 
CD45, and Ter119 antibodies (eBioscience), PE-conjugated anti-Sca-1 antibody 
(eBioscience), and Alexa 647-conjugated anti CD49f antibody (Biolegend). All 
antibody incubations, washes, and flow cytometric analyses were performed in 
cell sorting buffer (2% FBS in PBS). Fluorescence-activated cell sorting was 
conducted on a BD FACSAria I SORP, and cells were sorted into DMEM+20% 
FBS. Primary antibody labeling for cell sorting was conducted by incubation for 
20 minute on iced with antibody dilution according to manufacturer’s suggestions 
in a volume of 100 µl per 105-108 cells in cell sorting buffer.  The cells were 
washed in 1 ml ice-cold cell sorting buffer, resuspended in 0.5 ml cell sorting 
buffer, and analyzed. 
Histology    
Prostaspheres were fixed with 4% paraformaldehyde-PBS solution for 30 
minutes.  The fixed spheres were pelleted and mixed with Histogel.  After 
solidifying at room temperature, the Histogel pellets were serially dehydrated, 
embedded in paraffin, and sectioned as described (29).  For general histology, 
slides were re-hydrated and stained with hematoxylin and eosin (H&E). For 
immunostaining, the antigens were retrieved by boiling in citrate buffer (pH 8.0) 
for 20 minutes. The source and concentration of primary antibodies are: mouse 
anti-p63 (1:150 dilution) from Santa Cruz (Santa Cruz, CA), rabbit anti-
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phosphorylated ERK (1:200 dilution), rabbit anti-phosphorylated AKT (1200 
dilution), mouse anti-Ki67 (1:200 dilution), rabbit anti-β-Catenin (1:200 dilution), 
and anti-cleaved-Caspase 3 (1:200 dilution) from Cell Signaling Technology.  
The ExtraAvidin Peroxidase System (Sigma) and fluorescence-conjugated 
secondary antibodies (Invitrogen) were used to visualize specifically bound 
antibodies.  For the immunofluorescence staining, the nuclei were counter 
stained with To-Pro 3 before being observed under a confocal microscope 
(Zeiss LSM 510). 
Western blotting    
Prostaspheres were homogenized in RIPA buffer (50 mM Tris-HCl buffer pH 7.4, 
1% NP40, 150 mM NaCl, 0.25% Na-deoxycholate, 1 mM EGTA, 1 mM PMSF), 
and the extracted proteins were harvested by centrifugation.  Samples 
containing 30 μg proteins were separated by SDS-PAGE and electroblotted onto 
PVDF membranes for Western analyses with the indicated antibodies.  The 
dilutions of the antibodies are: anti-phosphorylated ERK1/2, 1:1000; anti-
phosphorylated AKT, 1:1000; anti-ERK1/2, 1:1000; and anti-AKT, 1:1000 (Cell 
Signaling Technology).  After being washed with TBST buffer to remove 
nonspecific antibodies, the membranes were then incubated with the 
horseradish peroxidase conjugated rabbit antibody at room temperature for 1 
hour.  The specifically bound antibodies were visualized by using the ECL-Plus 
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chemoluminescent reagents.  The films were scanned with a densitometer for 
quantitation. 
RNA expression    
Total RNA was isolated from prostaspheres using the TRIzol RNA isolation 
reagents (Life Technologies).  The first-strand cDNAs were reverse transcribed 
from the RNA template using SuperScript III reverse transcriptase (Invitrogen, 
Carlsbad, CA) and random primers according to manufacturer’s protocols.  Real-
time PCR analyses were carried out using the Fast SYBR Green Master Mix 
(Life Technologies) as instructed by the manufacturer.  Relative abundances of 
mRNA were calculated using the comparative threshold (CT) cycle method and 
were normalized to β-actin as the internal control.  The mean±sd among at least 
three individual experiments are shown. 
Statistical analysis    
Statistical analysis was performed using the two tailed t test, with significance 
set to P<0.05.  Error bars indicate standard deviation. 
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Results 
FGF signaling promotes prostasphere formation 
The FGF7/10-FGFR2 signaling axis is important in prostate development and 
maintenance of tissue homeostasis in the prostate (45,80,81).  To determine 
whether FGF signaling was required for prostasphere formation, FGF7 or 
FGF10 was added to the culture medium at a concentration of 10 ng/ml.  Both 
FGF7 and FGF10 significantly increased the number and size of prostaspheres 
(Fig. 3.1A).  This indicated that FGF signaling promoted prostasphere formation 
and growth of individual spheres. 
To determine which FGFR isoform mediates FGF signaling, we employed RT-
PCR analyses to examine the expression of FGFR isoforms in prostaspheres 
and primary prostate cells.  The results revealed that Fgfr1 and Fgfr2 were 
expressed in prostaspheres and primary prostate cells; Fgfr3 and Fgfr4 were 
detectable only in the primary prostate cells (Fig. 3.1Ba).   
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Fig. 3. 1. FGF promotes prostasphere formation and growth. 
A. FGF7 (F7) or FGF10 (F10) was added to the culture medium (10 ng/ml).  Sphere 
numbers per 100 cells were calculated (a) and sphere sizes (b) were measured at day 
10.  B. RT-PCR (a) and real-time RT-PCR (b) analyses of the indicated gene 
expression in primary prostate cells (P0) and prostaspheres of the 1st (P1) and 8th (P8) 
generations.  C. Real-time RT-PCR analyses of Fgfr1 expression in primary prostate 
cells and prostaspheres.  M, DNA molecular weight markers; B, basal epithelial cells; L, 
luminal epithelial cells; St, stromal cells, Sp, prostasphere cells; *, P≤0.05.  
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In addition, Frs2α, an adaptor protein required for the FGFR to activate ERK and 
PI3K/AKT pathways, was also expressed in prostaspheres (Fig. 3.1Ba).  While 
Fgfr2 expression remained stable in primary, P1 and P8 prostaspheres, Fgfr1 
expression was reduced in P8 prostaspheres (Fig. 3.1Bb).  Real time RT-PCR 
analyses of primary prostate cells showed that Fgfr1 was predominantly 
expressed in stromal cells (Fig. 3.1C).  However, basal cells and prostaspheres 
also had a trace amount of Fgfr1 expression. 
 
Inhibition of FGF signaling impairs self-renewal of prostaspheres 
To determine whether FGF signaling was critical in prostasphere formation, 
spheres were treated with FGFR tyrosine kinase inhibitor 341608.  The results 
showed that prostasphere formation was suppressed by 341608 (Fig. 3.2A).  
Real-time RT-PCR analyses revealed that the inhibitor concurrently increased 
expression of CK18 and AR and decreased expression of P63 (Fig. 3.2B), 
suggesting a transition from basal to luminal cells.  To further test the role of 
FGFR signaling in basal cell maintenance, we treated the K5H2B/GFP reporter-
bearing prostate spheres with FGFR inhibitors.  The GFP+ cells were reduced in 
the inhibitor group (Fig. 3.2C).  This indicated that inhibition of FGF signaling in 
prostasphere cells led to loss of CK5 expression, suggesting that the cells 
underwent differentiation. 
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Fig. 3. 2. Inhibition of FGF signaling suppresses prostasphere formation. 
A.  Prostasphere cultures were carried out with or without the indicated inhibitor for 6 
days.  Spheres with a diameter greater than 60 µm were scored (a).  Representative 
spheres were shown in b.  B.   Real-time RT-PCR analyses of the indicated genes 
expression in prostaspheres with or without treating with 500 nM FGFR inhibitors.  C. 
K5H2B/GFP spheres were treated with 500 nM FGFR inhibitors and GFP positive cells 
were detected by FACS (a&b).  The quantitative data are shown in panel c. D. The 
prostasphere cultures were treated with 500 nM FGFR inhibitor and phosphorylation of 
ERK and AKT was analyzed with Western blot (a) or immunostaining (b) analyses.  E. 
Prostaspheres were cultured with or without 10µm ERK or AKT inhibitors.  Rev 
indicates that the inhibitors were removed 6 days later.  Representative pictures are 
shown in panel a and real-time RT-PCR analyses of the indicated genes expression are 
shown in panel b. F. Panel a, primary Frs2cn and Frs2f/f prostate cells were cultured 
in Matrigel and the spheres were quantitated at day 10.  Panel b, prostate cells 
prepared from Frs2cn prostate were cultured in the presence of absence of 10 ng/ml 
FGF7 or FGF10.  The sphere numbers were scored at day 10.  Panel c. Total RNA 
extracted from Frs2f/f or Frs2cn prostates were subjected to real time RT-PCR of the 
indicated genes.  Panel d, FACS analyses showing reduced P-bSCs in individual 
prostate lobs of Frs2αCN prostates.  AP, anterior prostate; VP, ventral prostate; DLP, 
dorsolateral lobes; Ctrl, solvent control;  Ai, AKT inhibitor; Ei, ERk inhibitor; Fri, FGFR 
inhibitor; pERK, phosphorylated ERK; pAKT, phosphorylated AKT; AR, androgen 
receptor; WT, Frs2αf/f; CN, Frs2αCN; Data are normalized with α-actin loading control 
and expressed as mean±sd from triplicate samples;   *, P≤0.05. 
  
45 
 
 
 
Fig. 3.2.  Continued. 
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We then employed Western blot and immunostaining analyses to determine 
whether activation of the ERK or PI3K/AKT pathway, the two major signaling 
pathways downstream of the FGFR, was affected by FGFR inhibition in 
prostasphere (Fig. 3.2D).  Both analyses revealed that only phosphorylated 
ERK, but not phosphorylated AKT, was compromised by FGFRi treatment (Fig. 
3.2D).  To further clarify whether the two pathways contributed to prostasphere 
growth, SL327, an ERK inhibitor (ERKi), or LY294002, an AKT inhibitor (AKTi) 
was added to the sphere culture medium for 6 days.  The results indicated that 
both ERKi and AKTi suppressed prostasphere growth (Fig. 3.2Ea).  This was 
despite the fact that inhibition of FGFR signaling did not reduce phosphorylation 
of AKT.  Interestingly, withdrawal of AKTi, but not ERKi, partially restored sphere 
formation.  This suggested that the effect of AKTi on prostasphere suppression 
was reversible while that of ERKi was irreversible.  The result was consistent 
with a previous report that suppressing AKT signaling compromised proliferation 
of prostate sphere-forming cells without affecting cell survival (82).  However, 
both pathways had pro-differentiation functions in prostaspheres (Fig. 3.2Eb). 
FRS2 is an adaptor bridging FGFR tyrosine kinases and downstream signaling 
pathways.  To determine whether FRS2 was required for prostasphere 
formation, Frs2 alleles were tissue-specifically ablated in prostate epithelial 
cells using Nkx3.1Cre as described (83).  Ablation of Frs2α significantly reduced 
the sphere forming activity of primary prostate cells (Fig. 3.2Fa).  In addition, 
FGF7 and FGF10 failed to promote sphere forming activity in Frs2 null cells, 
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suggesting that FRS2 was required for FGF7/10 to promote prostasphere 
formation and growth (Fig. 3.2Fb).  RT-PCR analyses further demonstrated that 
ablation of Frs2α reduced expression of stem cell markers in the prostate, 
including Sca-1, CD49f, CD44, and CD133, as well as the basal cell 
characteristic CK14 (Fig. 3.2Fc).  Furthermore, Sca-1+/CD49f+ cells were 
reduced in all the lobes of Frs2α null prostates (Fig. 3.2Fd). 
 
Ablation of FGF signaling specifically in P63-expressing cells suppresses 
prostasphere formation 
Since sphere-forming cells expressed basal cell characteristic P63, and P63-
expressing cells were capable of giving rise to all cell types in the spheres, we 
then investigated whether FGFR1 and FGFR2 in P63+ basal cells played a role 
in prostasphere formation.  Prostaspheres derived from mice bearing P63CreERT2 
and either Fgfr1 floxed (Fgfr1f/f), or Fgfr2 floxed (Fgfr2f/f), or both (Fgfr1/2f/f) were 
treated with 4-OHT to delete the Fgfr1f/f and/or Fgfr2f/f alleles.  PCR analyses 
showed that the floxed sequences were deleted in the cells bearing 
Fgfr1f/f/P63CreERT2, Fgfr2f/f/P63CreERT2, and Fgfr1/2f/f /P63CreERT2 alleles (Fig. 3.3A), 
which are hereafter designated as Fgfr1bKO, Fgfr2bKO, and Fgfr1/2bKO, 
respectively.  The results showed that deleting Fgfr2 or both Fgfr1 and Fgfr2 
reduced sphere-forming activities, indicating that intact Fgfr2 alleles were 
required for prostasphere formation (Fig. 3.3Ba).   
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Fig. 3. 3. FGFR2 signaling is required for prostasphere formation. 
A. PCR analyses of gene ablation in prostaspheres.  B. Prostaspheres were cultured in 
the presence of absence of 4-hydroxytamoxifen to induce gene ablations.  Relative 
sphere forming unites were calculated (a) and morphology of the spheres were shown 
(b).  C.  Real-time RT-PCR analyses of Fgfr1 and Fgfr2 expression in the indicated cells 
with or without 4-hydroxytamoxifen treatment.  OHT, 4-hydroxytamoxifen; *, P≤0.05; 
data shown represents means ± sd from three mice. 
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Deleting Fgfr1 alone did not affect prostasphere formation.  In addition, deleting 
Fgfr2, or both Fgfr1 and Fgfr2, but not Fgfr1, at day 1 of primary culture impaired 
sphere integrity (Fig. 3.3Bb).  Real-time RT PCR revealed that ablation of Fgfr1 
resulted in elevated Fgfr2 expression.  In contrast, the deletion ofFgfr2 in 
prostaspheres caused the concomitant decline of Fgfr1 expression (Fig. 3.3C). 
 
FGFR2 signaling in P-bSCs upregulates the Wnt pathway and suppresses 
apoptosis 
Wnt signaling enhances the self-renewal of prostate basal/stem cells and 
promotes expansion of “triple positive” (CK5+, CK8+, p63+) prostate progenitor 
cells (84).  The basal progenitor cells have high Wnt signaling activity that is 
positively correlated with the basal cells number (85).  Interestingly, ablation of 
Fgfr1 in p63-expressing cells increased, while ablation of Fgfr2 reduced, β-
catenin levels as shown by qPCR (Fig. 3.4Aa) and immunofluorescence staining 
(Fig. 3.4Ba).  We reported earlier similar results in dental epithelial stem cells 
(77).  Together with the data that Fgfr2 expression was increased in Fgfr1 
ablated cells (Fig. 3.3C), the results indicated that FGFR2 enhanced Wnt 
signaling and enhanced self-renewal of P-bSCs.  
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Fig. 3. 4. FGFR2 signaling in P-bSCs upregulates the Wnt pathway and 
suppresses apoptosis. 
A.  The indicated prostaspheres treated with 4-hydroxytamoxifen at day 2 after 
inoculation were harvested at day 10.  Expression of β-catenin or Bcl-2 was assessed 
by real-time RT-PCR.   B. Immunostaining with anti-β-catenin or anti-c Caspase 3 
antibodies for the same spheres.  Ctrl, solvent control; OHT, 4-hydroxytamoxifen; c-
Caspase3, cleaved caspase 3; *, P≤0.05. 
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Real-time RT PCR and immunofluorescence staining showed that expression of 
BCl-2 was decreased (Fig. 3.4Ab) while cleaved Caspase 3 was increased upon 
Fgfr2 deletion or Fgfr1/2 double deletion (Fig. 3.4Bb), indicative of augmented 
cell apoptosis in the spheres.   
Thus, the results suggested that loss of FGFR2 signals promoted P-bSC 
apoptosis.  Although both were induced by the loss of FGFR2 signaling, whether 
the loss of stemness and commitment to apoptosis have a causal link needs to 
be further investigated. 
 
FGFR2 is required for maintenance of basal cell homeostasis in adult 
prostates 
To assess the effect of ablation of Fgfr1 or Fgfr2 in basal cells in the adult 
prostate, mice carrying Fgfr1f/f-P63CreERT2, Fgfr2f/f-P63CreERT2, or Fgfr1/2f/f-
P63CreERT2 alleles were treated with tamoxifen for 5 consecutive days.  Real-time 
RT-PCR analyses showed that expression of Fgfr1 and Fgfr2 in the dissociated 
basal cells was reduced a week later (Fig. 3.5A). Prostate cells were dissociated 
and basal and luminal cell populations were analyzed with a cell sorter (Fig. 
3.5B).   
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Fig. 3. 5. FGFR2 is required for maintaining basal cell homeostasis in the adult 
prostate. 
A&B. The indicated mice were injected I.P. with tamoxifen for 5 consecutive days at the 
age of 8 weeks.  The prostates were harvested a week later and isolated basal cells 
were subjected to RT-PCR analyses (A) or FACS analyses for cellular compositions 
(B).  C. Immunostaining of P63+ cells in the indicated prostate with or without tamoxifen 
injection.  Representative pictures from three mice were shown.  D. Sphere-forming 
analyses of FACS-fractionated basal cells from mice with the indicated genotype.  F/F. 
homozygous floxed alleles; bKO, basal cell specific knock out; data represent means ± 
SD from three mice; *, P≤0.05. 
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Fig. 3.5. Continued. 
 
 
Deletion of both Fgfr1 and Fgfr2 reduced the number of basal cells by 38% and 
increased luminal cells by 14%.  The total number of stromal cells remained the 
same.  Ablation of Fgfr2 also alone caused a similar decrease of 39% in basal 
cells while luminal cells increased by 28%.  The single ablation of Fgfr1 had no 
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impact on cellular composition of the prostate.  P63 mmunostaining further 
confirmed the reduction in basal cells in Fgfr2 or Fgfr1/2 conditional knockout 
adult prostates (Fig. 3.5C).  Furthermore, the sphere-forming activity of Fgfr2 or 
Fgfr1/Fgfr2 double deleted basal cells was impaired (Fig. 3.5D).  Together, the 
results suggested that ablation of Fgfr2, but not Fgfr1, in vivo impaired basal cell 
homeostasis and enhanced basal-to-luminal cell differentiation.  Thus, 
modulation of FGF signaling in adult basal/progenitor cells can be a determinant 
in specification of cell lineage. 
 
Disruption of Fgfr2 in P63 expressing cells perturbs prostate 
morphogenesis 
To investigate whether FGF signaling in P63-expressing cells contributed to 
prostate development, two-week-old mice bearing Fgfr1/P63CreERT2, 
Fgfr2/P63CreERT2, or Fgfr1/2/P63CreERT2 alleles were injected I.P. with tamoxifen 
to activate the Cre recombinase.  Ablation of Fgfr2 reduced the size of the 
prostate by 20% at 6 weeks of age (Fig. 3.6A).  In addition, the complexity of 
epithelial enfolding and the ductal network were also reduced (Fig. 3.6B).  
Consistent with our in vitro sphere assay data, ablation of Fgfr2 in prostates in 
vivo induced apoptosis, as shown by the reduction of anti-apoptotic protein Bcl-2 
expression (Fig. 3.6C).   
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Fig. 3. 6. Disruption of Fgfr2 in P63 expressing cells perturbs prostate 
morphogenesis. 
A. Prostate versus body weight ratio showing ablation of Fgfr2 in basal cells 
compromised prostate growth.  B. Prostate tissues from 6-week-old mice were 
dissected, sectioned and H&E stained.  C. Real time RT-PCR analyses showing 
reduced expression of Bcl-2 in Fgfr2bKO prostate.  D. Immunostaining showing reduced 
P63+ basal cells (a) and Ki67+ proliferating cells (c) in Fgfr2bKO prostate. Average cell 
numbers calculated from three samples were shown in panels b and d, respectively.  E. 
Prostate sections of 6-week-old Fgfr1/2bKO mice were immunostained with anti-Ki67 
antibodies and the Ki67 positive cells were quantitated.  F.  Sphere-forming efficiency of 
the indicated primary prostate cells was analyzed.  Average numbers of positive cells 
were calculated from 3 individuals and expressed as mean ± sd.  *, P≤0.05   
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Fig. 3.6.  Continued. 
 
 
The Fgfr2bKO prostate also had reduced basal cells and proliferating cells, as 
demonstrating by P63 and Ki67 immunostaining, respectively (Fig. 3.6D). 
Similarly, double ablation of Fgfr1 and Fgfr2 also reduced cell proliferation in 
developing prostate (Fig. 3.6E), as well as decreased prostasphere-forming P-
bSCs (Fig. 3.6F).  Ablation of Fgfr1 alone in basal cells had no effect (data not 
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shown).  The results demonstrated that FGFR2 in p63+ basal cells was required 
for prostate development.  The results are in line with our previous reports that 
ablation of Fgfr2, but not Fgfr1 in prostate progenitor cells impairs prostate 
branching morphogenesis (45,86). 
 
Discussion 
Prostasphere culture is a method for study and quantitation of self-renewal  of 
both human and mouse P-bSCs (19,29,30).  In this report, we showed that FGF 
signals mediated by the FGFR2-FRS2α pathway were required for prostasphere 
formation, growth, and maintenance.  This indicates that FGF signals mediated 
by the FGFR2 isotype in particular are required for self-renewal and 
maintenance of P-bSCs.  In addition, we also demonstrated that FGFR2 
signaling was required for maintenance of basal cell homeostasis in the 
prostate.  Unlike the prostasphere culture that is suitable for P-bSCs, the 
recently reported organoid culture methods are suitable for luminal P-lSCs 
(34,41).  Interestingly, constitutive activation of Notch signaling improves the 
sphere-forming activity of luminal cells under the same sphere culture condition 
(82).  The hierarchy of the two P-SC populations and whether FGF signaling has 
similar roles in P-bSCs and P-lSCs remains to be characterized 
Chapter II has already shown the cellular differentiation from common progenitor 
cells, specifically P63-expressing prostate basal stem cells, to  daughter basal 
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cells and luminal cells. In this study, FGFR2 in P63-expressing cells safeguards 
prostate basal cell self-renewal, as well as ensures the proper differentiation 
from basal cells to luminal cells. Adult mouse prostate basal cells and luminal 
cells are independently self-sustained in their native microenvironment. 
However, external insults, such as inflammation, alters the differentiation 
program of basal cells. Acute prostatitis induces the differentiation of basal cells 
to luminal cells (87). Conditional ablation of Pten in prostate basal cells also 
promotes basal-to-luminal differentiation (39). Our study shows that conditional 
knockout of FGFR2 in prostate P63-expressing basal cells promotes basal-to-
luminal differentiation.  
FGFR1 and FGFR2 have different roles in prostate development (45,86) as well 
as in prostate cancer development. FGFR1 activation initiates early stages of 
tumor development while FGFR2 generally is associated with inhibition of tumor 
growth (88-90). Down-regulation of FGFR2 is associated with malignant 
progression in human prostate (91). Our data shows that down-regulation of 
FGFR2 prompts the differentiation from basal to luminal cells. FGFR2 may be 
among prostate cancer susceptibility genes in tumors fueled by basal stem cells 
due to lack of differentiation. 
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CHAPTER IV 
OVEREXPRESSION OF FGF9 IN PROSTATE EPITHELIAL CELLS 
AUGMENTS REACTIVE STROMA FORMATION AND PROMOTES 
PROSTATE CANCER PROGRESSION 
 
Introduction 
The prostate consists of epithelial and stromal compartments separated by a 
basement membrane. Cells in the two compartments maintain active two-way 
communication through paracrine mechanisms in which ligands and receptors 
are partitioned between the two compartments (92,93).  These precisely 
balanced reciprocal communications are critical for preserving tissue 
homeostasis.  It is well documented that the accumulation of somatic mutations 
in epithelial cells is able to cause adenocarcinoma.  Prostate carcinoma cells are 
surrounded by a complex microenvironment, called prostate reactive stroma, 
which includes extracellular matrix (ECM), diffusible growth factors and 
cytokines, and a variety of non-epithelial cell types.  The tumor 
microenvironment also has a profound influence on the development and 
progression of carcinomas (94) and PCa is no exception.  Tumor-associated 
reactive stroma emerges as early as the formation of pre-malignant prostatic 
intraepithelial neoplasia (PIN), and arises due to modulation of a large spectrum 
of cell signaling, either due to stimuli from epithelial cells or intrinsic genetic or 
epigenetic changes (95-99). Prostate reactive stroma promotes PCa progression 
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by supporting tumor cell proliferation, inducing a fibroblastic phenotype, 
remodeling the extracellular matrix, and augmenting metastasis (95).   
Fibroblast growth factor (FGF) signaling is essential for prostate development 
and prostate tissue homeostasis (45,83).  Deregulation of FGF signaling has 
been implicated in developmental disorders and tumorigenesis in various tissues 
(68).  Extensive evidence shows that abnormal expression of FGF or FGFR 
isoforms and activation of the FGF/FGFR signaling axis are associated with PCa 
development and progression (83,90,100-104).  Amplification of the Fgfr1 gene 
is frequently found in human PCa (105).  The acquisition of ectopic expression 
of FGFR1 in tumor epithelial cells stands out as the most frequent change 
among FGFR isotypes (106-109).  Forced expression of constitutively active 
FGFR1 or multiple FGF ligands has been shown to induce prostate lesions in 
mouse models (78,89,90,110-115).  Ablation of Fgfr1 or Frs2 significantly 
reduces mouse PCa development and progression induced by T antigens 
(83,86).  However, how aberrant FGF signals contribute to PCa progression is 
still not fully understood. 
Accumulating evidence supports a role for FGF9 in PCa progression and 
metastasis. Previous studies have shown that FGF9 mediates osteogenesis 
induced by androgen receptor-negative human PCa cells (110).  In addition, 
FGF9-positive PCa shows higher risk of biochemical recurrence (116).  In spite 
of the correlation between FGF9 and PCa progression and bone metastases, 
whether overexpressed FGF9 initiates prostate tumorigenesis is still elusive.  To 
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study whether FGF9 overexpression contributes to PCa initiation and 
progression, transgenic mice expressing FGF9 in prostate epithelial cells were 
generated and crossed with the TRAMP mouse model.  Forced expression of 
FGF9 in the prostate led to PIN in a time dependent manner.  Furthermore, it 
augmented the formation of reactive stroma and accelerated PCa progression in 
TRAMP mice.  Both in vivo and in vitro data showed that activation of c-Jun-
dependent TGF-β1 expression in prostate stromal cells by FGF9 constituted a 
paracrine loop that contributed to PCa progression.  Moreover, in silico analyses 
of the TCGA database demonstrated that expression of FGF9 was correlated 
with that of TGF-β1 and its downstream effectors.  Together, the results support 
a mechanism by which FGF9 overexpression in PCa contributes to PCa 
progression and metastasis.  
 
Materials and Methods 
Animals    
All animals were housed in the Program for Animal Resources of the Institute of 
Biosciences and Technology, and were handled in accordance with the 
principles and procedures of the Guide for the Care and Use of Laboratory 
Animals.  All experimental procedures were approved by the Institutional Animal 
Care and Use Committee.  Mice carrying the FGF9 and the TRAMP transgenes 
were bred and genotyped as described (69).  Primers are, FGF9 forward: 
62 
 
 
CTTTGGCTTAGAATATCCTTA; FGF9 reverse: 
AGTGACCACCTGGGTCAGTCC; TRAMP forward: 
CCGGTCGACCGGAAGCTTCCA CAAGT; TRAMP reverse: 
CTCCTTTCAAGACCTAGAAGGTCCA.  Prostate tissues and metastatic tumors 
were harvested after the animals were euthanized by CO2 asphyxiation.  Nude 
mice were purchased from Charles River Laboratory and maintained in standard 
conditions according to the Institutional Guidelines. 
Generation of transgenic mice    
The full-length rat FGF9 cDNA including the Kozak sequence was amplified by 
PCR using rat FGF9 cDNA as the template.  After digestion with BamHI and 
EcoRV, the PCR product was subcloned into the pBluescript SK vector and 
sequenced.  The insert was excised with the two restriction enzymes and cloned 
into the SSI vector (89).  The ARR2PB-FGF9 transgene was excised with BssHII 
restriction enzyme and purified for pronuclear microinjection.  Fertilized eggs 
were collected from FVB females and pronuclei were injected with the ARR2PB-
FGF9 DNA construct.  Injected eggs were transferred into pseudo-pregnant 
Swiss/Webster females for full-term development. Genomic DNA was purified 
from tails of founder mice at day 7 after birth and screened by PCR. 
Histology    
Prostates were dissected and sectioned for histological analyses as previously 
described (45,69).  Hematoxylin and Eosin staining, immunohistochemical 
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analyses, and in situ hybridization were performed on 5-µm sections mounted 
on Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA).  Antigens were 
retrieved by incubation in citrate buffer (10 mmol/L) for 20 minutes at 100 °C or 
as suggested by antibody manufacturers.  The sources and concentrations of 
primary antibodies used are: anti-α-smooth muscle actin (1:1) from Sigma (St 
Louis, MO); anti-Vimentin (1:200), anti-E-cadherin (1:200) from Cell Signaling 
Technology; anti-androgen receptor (1:200) from Santa Cruz; anti-CD31 (1:200) 
from Abcam; anti-Ki67 (1:500) from Novus Biologicals.  For 
immunofluorescence, the specifically bound antibodies were detected with FITC-
conjugated secondary antibodies and visualized on a Zeiss LSM 510 Confocal 
Microscope.  For immunohistochemical staining, specifically bound antibodies 
were detected with biotinylated anti-Rabbit IgG or biotinylated anti-mouse IgG 
antibodies (Vector labs).  The signal was enhanced using the VECTASTAIN 
ABC system and visualized with a VECTOR NovaRED Substrate kit.  Prostate 
lesion grading was performed as described (17,117). 
Isolation of primary stromal cells   
Prostates were dissected and single primary prostate cells were obtained as 
described (118).  Briefly, prostates dissected from 4 to 8-month-old male mice 
were minced with steel scissors, followed by incubation with 1 mg/ml 
collagenase (Sigma) in 10 ml DMEM with 10% FBS at 37 °C for 90 minutes.  
Cells were washed with PBS and further digested with 0.25% trypsin/EDTA for 
10 minutes at 37 °C.  After inactivation of trypsin by FBS, cells were passed 
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through a 40-μm cell strainer, washed with DPBS (Sigma) and seeded in 10-cm 
cell plates.  After overnight incubation at 37 oC, the unattached cells were 
removed and only attached stromal cells remained in culture.  Both mouse 
primary prostate stromal cells and human prostate stromal HPS-19I cells were 
cultured as described (95). 
Luciferase assay    
A pGL3 plasmid containing the full-length TGF-β1 promoter region (119)  was 
kindly provided by Dr. Zhengxin Wang, University of Texas MD Anderson 
Cancer Center. Luciferase assay was done following the instructions of dual-
luciferase reporter assay system (Promega). 
Immunoblotting    
Dissected prostate tissues or prostate cancer cells were homogenized in RIPA 
buffer (50 mM Tris-HCl buffer pH 7.4, 1% NP40, 150 mM NaCl, 0.25% Na-
deoxycholate, 1 mM EGTA, and 1 mM PMSF).  Extracted soluble proteins were 
harvested by centrifugation. Samples containing 50 µg proteins were separated 
by SDS-PAGE and electroblotted onto PVDF membranes for Western Blotting 
analysis with the indicated antibodies.  The dilutions of the antibodies are: anti-
cJun, 1:1000; anti-Slug, 1:1000; anti-TGFβ1, 1:1000; anti-pSmad2/3: 1:1000; 
and anti-β-Actin, 1:3000.  Specific bands were visualized using the ECL-Plus 
chemoluminescent reagents.  The films were scanned with a densitometer and 
the bands were quantified using Image J software (NIH). 
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Gene expression    
For in situ hybridization, paraffin-embedded tissue sections were rehydrated, 
followed by 10 µg/ml protease K digestion for 15 minutes at room temperature.  
After prehybridization at 65 °C for 2 hours, the hybridization was carried out by 
overnight incubation at 65 °C with 1 µg/ml digoxigenin-labeled RNA probes for 
the FGF9 transgene.  Nonspecifically bound probes were removed by washing 
three times with 0.1X DIG washing buffer at 65 °C for 30 minutes.  Specifically 
bound probes were detected by an alkaline phosphatase-conjugated anti-
digoxigenin antibody (Roche, Indianapolis, IN). 
For real-time RT-PCR analyses, total RNA was extracted from prostates using 
the TRIzol RNA isolation reagents (Life Technologies).  The first-strand cDNAs 
were reverse transcribed from 1 µg RNA templates using the SuperScript III 
reverse transcriptase (Invitrogen, Carlsbad, CA) and random primers according 
to manufacturer’s protocols. Real-time RT-PCR analyses were carried out using 
the Fast SYBR Green Master Mix (Life Technologies) as instructed by the 
manufacturer. 
Chromatin immunoprecipitation (ChIP) assays    
For the ChIP experiments, extracts were prepared from primary prostate stromal 
cells.  ChIP assays were carried out with the EZ-Magna ChIP Kit (Millipore, 
Billerica, MA) according to the manufacturer’s protocols. The following set of 
real-time PCR primers specifically for the c-Jun binding regions on the TGF-β1 
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promoter was used: TGFβ1-Forward: GGCTGCATCTCCAAGCATT and TGFβ1-
Reverse: GGTTCTCATCTCCCACTCACTC. 
 
Results 
Overexpression of FGF9 disrupts prostate tissue homeostasis in an 
expression level- and time-dependent manner 
To determine whether FGF9 overexpression caused prostate lesions, we 
generated 8 strains of ARR2PBi-FGF9 transgenic mice, in which expression of 
FGF9 in prostate epithelial cells was driven by the ARR2PB composite probasin 
promoter as described (89).  Among them, TG5 and TG12 highly expressed the 
FGF9 transgene; TG3, TG8, and TG9 expressed the transgene at moderate 
levels; and TG1, TG2, and TG10 expressed the transgene at low levels (Fig. 
4.1A).  The Fgf9 expression level in TG12 was shown in Fig. 4.1B.  Around the 
age of 3-8 months, the mice suffered penis protrusion (Fig. 4.1C) and the 
prostate was fused with the seminal vesicles (Fig. 4.1Da).  H&E staining 
revealed that the prostate developed severe hyperplasia in both stromal (Fig. 
4.1Db) and epithelial compartments (Fig. 4.1Dc).  Since both TG5 and TG12 
that expressed FGF9 at high levels were infertile, the line TG8 with moderate 
expression levels of FGF9 was chosen for the following studies and hereafter is 
designated as F9TG. 
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Fig. 4. 1. Overexpression of FGF9 leads to fusion of the prostate and seminal 
vesicles. 
A. Generation of FGF9 transgenic founders. Expression of the transgene was examined 
with RT-PCR analysis.  Note that the two high expressers were infertile. B. Agarose gel 
electrophoresis of PCR products showing expression levels of the FGF9 transgene.  C. 
Real time RT-PCR analyses of FGF9 expression in TG12 founder prostate. D. TG12 
founder developed a penis protrusion.  E. Fusion of the prostate with seminal vesicles in 
TG12 founder. F. H&E staining showing hyperplasia in both stromal and epithelial 
compartments.  L, low expression level; M, moderate expression level; H, high 
expression level; WT, wildtype; SV, seminal vesicles. 
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In situ hybridization demonstrated that the Fgf9 mRNA was highly expressed in 
the prostate epithelium of F9TG mice (Fig 4.2A).  In contrast, expression of 
endogenous Fgf9 mRNA was below the detection limit under the same 
condition.  Real-time RT-PCR analyses showed that the expression level of Fgf9 
in F9TG prostate was 30 fold higher than that of non-transgenic littermates.  No 
apparent difference was observed in the histology and tissue size between 
F9TG and control prostates at young adult stages.  However, mild hyperplasia 
was detected in the ventral prostates of 8-month-old F9TG mice (Fig. 4.2B).  At 
11 months of age, F9TG prostates displayed anomalies ranging from multifocal 
hyperplasia to low grade PIN, with atypical larger cells with irregular 
hyperchromatic nuclei.  At 18 months, F9TG prostates (n=4) progressed to high-
grade PIN and invasive carcinoma as shown by the loss of the boundary 
between epithelium and stroma compartments (Fig. 4.2B).  Highly pleomorphic 
atypical cells arranged in a cribriform pattern were observed in the lumen.  
Extracellular matrix remodeling and stromal hypercellularity was notable 
adjacent to the invasive carcinoma.  In contrast, WT prostates only showed a 
few mild hyperplasia lesions.  Quantified analyses of 18-month-old mice showed 
that F9TG prostates developed more prostate lesions, ranging from low grade 
PIN, high grade PIN, to invasive carcinoma, than control prostates (Fig. 4.2C). 
Compared with the control prostate, cells in the F9TG prostate were more 
proliferative (Fig. 4.2D&E).  At 11 months of age, F9TG prostates possessed 
nearly four times as many proliferating epithelial cells as control prostates.   
69 
 
 
 
 
Fig. 4. 2. Forced expression of FGF9 in prostatic epithelial cells disrupts prostate 
tissue homeostasis. 
A. In situ hybridization demonstrates expression of Fgf9 mRNA in mouse prostate.  
Inserts are negative control using sense probes.  B. H&E staining demonstrating 
prostate lesions in F9TG prostates at 8 months, 11 months, and 18 months.  Arrows 
indicate hyperplasia, LGPIN, and HGPIN. Inserts are high magnification views from the 
same slides.  C. Quantitation of the histology of 18-month-old WT and F9TG prostates.  
N=4 per group.  D. Immunostaining of Ki67 showing proliferating epithelial cells in 11-
month-old WT and F9TG prostates.  E. Quantitation of Ki67 positive cells in F9TG and 
control prostates at the indicated ages.  F. Ki67 staining showing proliferating cells in 
the stromal compartment.  G. Immunohistochemical or immunofluorescence analysis 
with antibodies against androgen receptor, E-cadherin, α-smooth muscle actin, or CD3 
of 18-month-old WT and F9TG prostates.  WT, wild type; F9TG, FGF9 transgenic mice; 
HGPIN, high grade prostatic intraepithelial neoplasia; LGPIN, low grade prostatic 
intraepithelial neoplasia; F9TRAMP, FGF9tg/TRAMP bigenic mice; scale bars, 50 µm. 
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Fig. 4.2.   Continued. 
 
 
Moreover, stromal proliferation became prominent as shown by the Ki67 staining 
of the cells that did not expressed E-cadherin (Fig 4.2Fa,b).  Both androgen 
receptor (Fig. 4.2G,b) and E-cadherin (Fig. 4.2Gc,d) expressions in F9TG 
prostates appeared to be similar to that of control prostates.  However, the 
smooth muscle-like stromal cells were reduced adjacent to the high-grade PIN 
lesions (Fig. 4.2Ge,f).  Clusters of CD3 positive cells were particularly notable in 
the stromal region of F9TG prostates (Fig. 4.2Gg,h), indicating the presence of T 
lymphocyte infiltrations.  Together, the data suggest that overexpressing FGF9 
disrupts prostate tissue homeostasis in both epithelial and stromal 
compartments. 
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Overexpressed FGF9 promoted initiation and progression of TRAMP 
tumors 
To determine whether overexpression of FGF9 contributed to PCa initiation and 
progression, F9TG mice were crossed with TRAMP mice to generate 
FGF9/TRAMP bigenic mice (hereafter designated as F9TRAMP).  In situ 
hybridization (Fig. 4.3A) and real-time RT-PCR (Fig. 4.3B) analyses revealed 
that FGF9 was highly expressed in the epithelium of the F9TRAMP prostate.  
F9TRAMP mice had a median survival time of 218 days, which was shorter than 
that of TRAMP mice that had a median survival time of 234 days.  Although 
similar at early ages, the average weight of F9TRAMP prostates (n=13) was 
heavier than that of TRAMP prostates (n=10) at the age of 6 months or older 
(Fig. 4.3C).  Since the majority of lesions in the TRAMP prostate were initiated in 
ventral prostate (17), H&E staining was carried out to analyze the lesion 
development in F9TRAMP ventral prostates at the ages of 3, 4, and 6 months 
(Fig. 4.3D).  Apoptotic bodies were prominent in 4-month F9TRAMP ventral 
prostates.  Cribriform architecture was seen in 6-month-old TRAMP ventral 
prostates, while F9TRAMP mice already developed poorly differentiated prostate 
cancer, composed of sheets of cells with little or no glandular formation. To 
quantitate the lesion development, the standardized prostate lesion grading 
system (17,117) was employed to assess the severity of the lesions at the ages 
of 3 and 6 months (Fig. 4.3E).  The F9TRAMP prostates had more high-grade 
lesions in both groups than the TRAMP prostates.  About 54% of the F9TRAMP  
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Fig. 4. 3. Overexpression of FGF9 in prostatic epithelial cells promotes PCa 
progression in mice. 
A. In situ hybridization showing expression of Fgf9 mRNA in mouse prostates.  B. Real-
time RT-PCR analyses of Fgf9 expression in TRAMP and F9TRAMP prostates at 4 
months.  C. H&E staining of TRAMP and F9TRAMP prostates at the ages of 3, 4, and 6 
months.  D. Statistical analysis of prostate/body weight ratio of TRAMP and F9TRAMP 
prostates at the ages of 4, 5, and 6 months.  E. Quantitative analyses of prostate 
lesions of TRAMP and F9TRAMP mice at the age of 3 or 6 months. N=5 per group.   F. 
Immunostaining comparing AR, P63, and Ki67 expression in TRAMP and F9TRAMP 
prostates.  Statistical analyses of proliferating cells in TRAMP and F9TRAMP prostates 
at the indicated ages.  Scale bars, 50 µm 
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Fig. 4.3.  Continued. 
 
 
prostate had poorly differentiated (PD) carcinomas, while only 20% TRAMP 
mice developed PD carcinomas at 6 months.  No obvious defect was observed 
in AR expression and localization in the F9TRAMP prostate (Fig. 4.3Fa,b).  
However, the number of P63-expressing basal cells was reduced in F9TRAMP 
prostates (Fig. 4.3Fc,d), which was consistent with the notion that basal cells 
were diminished in PCa (120,121).  Moreover, cells in the F9TRAMP prostate 
were more proliferative than in the TRAMP prostate (Fig. 4.3Fe-g). 
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Overexpression of FGF9 promoted metastasis of TRAMP prostate tumors 
To determine whether F9TRAMP tumors were more metastatic, we then 
examined the metastatic tumors in F9TRAMP and TRAMP mice at the times of 
sacrifice.  The metastasis-free curve showed that F9TRAMP mice (n=54) 
developed metastases earlier than TRAMP mice (n=39) (Fig. 4.4A).  Moreover, 
the frequency of metastasis was higher in F9TRAMP mice than in TRAMP mice 
at all inspection times.  In situ hybridization showed that Fgf9 mRNA was 
expressed in metastatic PCa cells in both F9TRAMP and TRAMP mice but not 
adjacent non-cancerous tissues (Fig. 4.4Ba,b). The metastatic PCa cells in both 
mice expressed AR and T-antigens (Fig. 4.4Cc-f).   Intriguingly, most of the 
metastatic tumors were positive for synaptophysin staining and negative for P63 
staining (Fig. 4.4Cg-j).  This indicates the presence of neuroendocrine 
differentiation in metastatic tumors, which is frequently observed in advance 
human PCa. 
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Fig. 4. 4. Overexpression of FGF9 promotes PCa metastasis in mice. 
A. Kaplan-Meier analysis of metastasis-free time in TRAMP and F9TRAMP mice.  B.  In 
situ hybridization showing Fgf9 expression in lymph node metastases of F9TRAMP and 
TRAMP tumors.  C. Immunostaining of the indicated proteins in lymph node metastases 
of F9TRAMP and TRAMP tumors.  Scale bars, 50 µm. 
 
 
TRAMP-C2 cells are derived from TRAMP tumors and express Fgf9 at a 
moderate level.  To further characterize the role of FGF9 in prostate 
tumorigenesis, expression of Fgf9 in TRAMP-C2 cells was depleted by infecting 
the cells with lentivirus bearing shRNA specific for Fgf9 mRNA (Fig. 4.5A).  The 
cells were then mixed with mouse urogenital sinus mesenchymal cells and 
grafted in the flanks of nude mice.  Eight weeks after the implantation, tumor 
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grafts were excised for analysis.  The graft size of the FGF9 depleted group was 
smaller than that of the control group (Fig. 4.5B).  Although no significant 
difference in general histology between the two groups was detected (Fig. 4.5C 
a,b), depletion of FGF9 compromised cell proliferation in the graft (Fig. 4.5Cc,d).  
In addition, the FGF9-depleted grafts had fewer CD31 positive endothelial cells 
than the control group, indicating compromised angiogenesis in the FGF9 
depleted graft (Fig. 4.5Ce,f), which was in agreement with a previous report that 
FGF9 induces VEGF-A expression in PCa (122).  Interestingly, immunostaining 
with anti-F4/80 antibodies revealed that depletion of FGF9 reduced macrophage 
infiltration in TRAMP-C2 grafts (Fig. 4.5Cg,h), implying a role of epithelial-
expressed FGF9 in reactive stroma formation and microenvironmental 
remodeling.  Trichrome staining revealed that the stroma of F9TRAMP prostates 
exhibited extensive collagen deposition, which is indicative of reactive stroma 
(Fig. 4.5D).  In addition, the well-organized smooth muscle layer surrounding the 
epithelial cells became fragmented with more vimentin-positive fibroblast-like 
cells (Fig. 4.5E).  Consistently, the F9TG prostates also exhibited a disrupted 
stromal compartment (Fig. 4.2Ff).  Together, the results indicate that 
overexpression of FGF9 is important for growth and metastasis of PCa, in part 
by modulating the tumor microenvironment. 
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Fig. 4. 5. Depletion of FGF9 suppresses tumorigenicity of TRAMP tumor cells. 
A. Real-time RT-PCR analyses for Fgf9 expression in TRAMP-C2 cells and FGF9 
depleted TRAMP-C2 cells.  B. Subcutaneous grafts of TRAMP-C2/UGM cells with or 
without FGF9 depletion.  Graft weight is mean ± sd from 3 grafts per group.  C. H&E 
and immunostaining of graft sections with the indicated antibodies.  D. Masson 
Trichrome staining of prostate sections of 4-month-old TRAMP or F9TRAMP mice, 
demonstrating excessive collagen deposition in the stromal compartment of F9TRAMP 
mice.  E. Co-staining of α-smooth muscle actin and vimentin in 4-month-old TRAMP 
and F9TRAMP prostates. UGM, urogenital mesenchymal cells; Ctrl, control; KD, 
knockdown; Scale bar, 50 µm. 
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FGF9 promoted the reactive stroma by modulating TGFβ1 signaling 
To investigate how FGF9 overexpression contributes to the two-way 
communication between the epithelium and the stroma in human PCa, LNCaP 
cells were forced to express FGF9 by transfection (Fig. 4.6A).  The transfected 
cells were separated into high FGF9-expressing cells (FGF9high) and low FGF9-
expressing cells (FGF9low) groups by limited dilution (Fig. 4.6A).  The cells were 
then cocultured with or without HPS-19I human prostate stromal cells in a 
transwell migration assay, in which the stromal cells were seeded in the bottom 
chamber and LNCaP in the upper chamber (Fig. 4.6B).  After incubation for 24 
hours, LNCaP cells that migrated through the membrane were stained and 
counted.  Both FGF9high and FGF9low cells exhibited a low baseline level of 
migration, though FGF9high cells possessed a slightly higher migration rate, 
which was consistent with a previous report (122).  However, significantly more 
FGF9high cells migrated through the membrane than FGF9low cells in the 
presence of HPS-19I cells (Fig. 4.6Be).  Our results suggest that FGF9 
promotes HPS-19I cells to release secretory factors that promote LNCaP cell 
migration. 
We next examined proteins potentially affecting LNCaP migration.  Expression 
of E-cadherin was equivalent between both LNCaP groups in the absence of 
HPS-19I cells.  However, when they are cocultured with HPS-19I cells, FGF9high 
cells expressed E-cadherin at a lower level than did FGF9low cells (Fig. 4.6Ca). 
This suggests that overexpressing FGF9 in LNCaP cells induced HPS-19I cells  
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Fig. 4. 6. Overexpression of FGF9 promotes the two-way communication between 
PCa and stromal cells. 
A. Real time RT-PCR analyses for Fgf9 expression in LNCaP cells. B. The indicated 
LNCaP cells were co-cultured with or without HPS-19I human prostate stromal cells in 
transwell assay.  LNCaP cells migrating through the membrane were stained (panel a) 
and C. quantitated from triplicate samples and presented as mean ± sd (panel b).  D. 
Real time RT-PCR analysis of LNCaP cells with or without HPS-19I cell coculture.  
FGF9high, high FGF9-expressing LNCaP cells; FGF9low, low FGF9-expressing LNCaP 
cells.  HPS, HPS-19I human prostate stromal cells.   SMA, α-smooth muscle actin. 
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to release factors that, in turn, promoted EMT in LNCaP cells.  LNCaP cells 
treated with exogenous FGF9 showed an increase of Snail1 expression (Fig. 
4.6Cb).  Real-time RT-PCR analyses showed that coculturing with LNCaP also 
changed the gene expression pattern in HPS-19I cells at an FGF9 expression 
level-dependent manner (Fig. 4.6Cc).   
Among the upregulated genes was TGFβ1, a key signaling molecule to induce 
reactive stroma that mediates the expression of many stromal derived factors, 
including FGF2, CTGF, BMP6, and IL6 (123-125).  Similarly, isolated stromal 
cells from F9TG prostate expressed TGFβ1 at higher levels than stromal cells 
isolated from non-transgenic mice (Fig. 4.7Aa).  In addition, treating wildtype 
prostate stromal cells with FGF9 increased TGFβ1 mRNA levels within 6 hours, 
further demonstrating the transcriptional upregulation of TGFβ1 by FGF9 (Fig. 
4.7Ab).  Blocking FGF receptor kinase activity with FGFR inhibitors diminished 
the induction effect of FGF9 on TGFβ1 expression (Fig. 4.7Ac).  To further 
determine whether FGF9 regulated TGFβ1 expression, 293T cells were 
transfected with a TGFβ1 reporter carrying the TGFβ1 promoter sequence 
driving luciferase expression.  Treating the cells with FGF9 increased expression 
of the reporter (Fig. 4.7B). 
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Fig. 4. 7. FGF9 promotes TGFβ1 expression in prostate stromal cells via 
upregulating cJun. 
A. Real time RT-PCR analysis of TGFβ1 expression demonstrating upregulation of 
TGF-β1 expression by FGF signaling.  Panel a, TGFβ1 in F9TG and wildtype prostates; 
panel b, mouse prostate stromal cells treated with 10 µg/ml FGF9 for the indicated time; 
panel c, mouse prostate stromal cells treated with vehicle control (Ctrl) or FGFR 
inhibitors (FGFRi) and then 10 ng/ml FGF9.  B. Luciferase reporter assay in 293T cells 
showing that FGF9 stimulated TGFβ1 promoter activity.  C. ChIP analysis showing 
FGF9 enhanced the binding of cJun to the TGF-β1 promoter in primary prostate stromal 
cells.  Panel a, real time PCR analysis; panel b, agarose gel electrophoresis showing 
specific DNA bands.  D. Western blot analyses of cJun and TGFβ1 expression in 
primary prostate stromal cells with or without FGF9 stimulation.  E. Real time RT-PCR 
analysis showing that cJun downregulation in HPS-19I cells suppressed TGFβ1 
expression.  F.  Real time RT-PCR analysis showing that FGFR inhibitor abrogated the 
induction of cJun expression by FGF9.  G. Western blot analysis demonstrating 
expression of the indicated proteins in WT, F9TG, TRAMP, F9TRAMP prostates at 
indicated ages.  H. Pearson correlation analysis of the TCGA dataset (downloaded from 
cBioPortal database) revealed a positive correlation between FGF9 and TGFβ1 (panel 
a) or vimentin (panel b) mRNA expression in human PCa.  Panel c, Pearson correlation 
analysis of another genome-wide study (126) revealed that the expression of FGF9 is 
positively correlated with TGFβ1, Twist1 and Smad2 expression.  Data are mean ± sd 
from triplicate samples.  Ctrl, control; FGFRi, FGFR inhibitor; F, F9TG; W, wildtype ;T, 
TRAMP; FT, F9TRAMP; *, P< 0.05. 
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Fig. 4.7.  Continued. 
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To identify the transcription factor(s) that mediated the induction of TGFβ1 
expression by FGF9 signaling, TFSEARCH (http://diyhpl.us/~bryan/irc/protocol-
online/protocol-cache/TFSEARCH.html) was used to predict the binding sites on 
the TGFβ1 promoter region for transcription factors that can be regulated by 
FGF signaling.  Two c-Jun binding sites were found within a 2-kb proximal 
region of the TGFβ1 promoter.  Treating mouse primary prostate stromal cells 
with FGF9 increased the binding of c-Jun to the TGF-β1 promoter (Fig. 4.7C), 
suggesting that c-Jun activation was involved in the regulation of TGFβ1 
expression by FGF9.  Moreover, FGF9 promoted both cJun and TGFβ1 
expression at the protein level in mouse primary prostate stromal cells (Fig. 
4.7D).  In line with this finding, depletion of cJun expression by siRNA 
compromised the induction of TGFβ1 expression by FGF9 (Fig. 4.7E).  Inhibition 
of FGFR activity also diminished cJun expression induced by FGF9 (Fig. 4.7F).  
Consistent with the in vitro cell culture data, both F9TG and F9TRAMP prostates 
exhibited a higher expression level of cJun and TGFβ1, as well as higher 
phosphorylated Smad2/3 levels (indicating elevated TGFβ signaling) (Fig. 4.7G).  
Together, our study demonstrates that overexpressing FGF9 in PCa cells 
induces expression of TGFβ1 via cJun in prostate stromal cells, which, in turn, 
promotes PCa cell migration. 
To determine whether the expression level of FGF9 was correlated with TGFβ1 
expression and stromal changes in human PCa, in silico analyses was carried 
out with data from the TCGA (cBioPortal) dataset.  Expression of FGF9 in 
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human PCa was positively correlated with TGFβ1 and vimentin expression (Fig. 
7Ha,b).  Furthermore, in a separate dataset including genome-wide sequencing 
of 57 prostate tumors and matched non-cancerous tissues (126), expression of 
Fgf9 was positively correlated with that of TGFβ1, Twist1, and Smad2 (Fig. 
7Hc).  This further indicates that FGF9 promotes EMT and reactive stroma 
formation in PCa. 
 
Discussion 
It has been reported that aberrantly expressed FGF9 has oncogenic and 
transformation activity in various human cancers, including ovarian endometrioid 
adenocarcinomas (127,128), ovarian cancer(129), a subset of human lung 
adenocarcinomas(130,131), brain tumor (132), and colon cancer cells(133). In 
particular, overexpression of FGF9 in human PCa predicts high bone metastasis 
and biochemical recurrence (110,116).  Although the correlation between FGF9 
and prostate cancer has been implied, how FGF9 promotes tumor epithelial-
stromal interactions that contribute to PCa progression is not clear.  In this study, 
by using in vivo mouse model, in vivo xenograft model, and molecular approach, 
we report that forced overexpression of FGF9 in prostate epithelial cells disrupts 
prostate tissue homeostasis and drives the oncogenic transformation. In the 
TRAMP model, FGF9 significantly expedites prostate cancer progression and 
metastases. It augments the formation of reactive stroma, exemplified by the 
collagen deposition, and an increase of vimentin positive cells. TGF-β1, a 
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characteristic factor in the prostate reactive stroma, is increased, concomitant 
with an increase of cJun. Moreover, the expression level of FGF9 is positively 
associated with that of cJun, TGFβ1, and Smad2 in human PCa. Together, our 
data provides the direct evidence that FGF9 is a causal factor of prostate cancer 
onset and progression. However, FGF9 alone is not sufficient to cause multi-
focal invasive adenocarcinoma and metastases, thus the signals that restrain 
the progression remains to be uncovered. 
Both F9TG and F9TRAMP prostates displayed highly proliferative epithelial 
cells. MAP kinase and PI3K-AKT pathways are the two major downstream 
signaling pathways that account for cell proliferation.  To determine whether 
FGF9-induced signals activate the MAP kinase and PI3K-AKT pathways, 
prostates were harvested from TRAMP and F9TRAMP mice at 4 months of age 
and subjected to immunoblotting analysis of phosphorylated ERK1/2 and AKT. 
Phosphorylation of ERK1/2 was increased in F9TRAMP prostates. By contrast, 
phosphorylation of AKT were comparable between TRAMP and F9TRAMP 
prostates. Similarly, exogenous FGF9 phosphorylated ERK, but not AKT in 
human prostate cancer cell line LNCaP cells. 
Our previous studies have shown the signaling from epithelial FGF9 to stromal 
FGFR3 potentially mediates epithelial-to-stromal communication in Dunning 
R3327 rat prostate tumors (134). To determine the receptors for FGF9, Fgfr1, 
Fgfr2, and Fgfr1/Fgfr2/Frs2α knockout MEF cells were stimulated with FGF9 and 
the cell lysate was subjected to immunoblotting. Only after triple knockout of 
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both FGFR1, FGFR2, and FRS2α, phosphorylation of ERK1/2 was abolished. 
These results suggested that FGFR1, FGFR2 and FRS2α work together to 
direct downstream MAPK pathway activation upon the stimulation of FGF9. 
Reciprocal communication between epithelial cells and stromal cells is influential 
in carcinogenesis. FGF9 in the epithelial cells remodeled the tumor 
microenvironment and potentiated the reactive stromal response.  The reactive 
stroma emerges due to a plethora of effectors, genetically or epigenetically, cell 
autonomously, or non-autonomously. The reactive stroma is a reservoir of 
inflammatory cells, angiogenic cells, nerve cells, smooth muscle cells, 
fibroblasts, extracellular matrix and cytokines. It provides a favorable 
environment for prostate epithelial cells to proliferate, break the epithelial 
barriers and metastasize to the distant organs. 
Due to the close coupling between the epithelium and stroma, during prostate 
cancer development, changes in epithelium therefore caused abnormality in the 
stroma, which is further validated by our study. These stroma alterations, in turn, 
affect the epithelium. As shown in our study, overexpression of FGF9 induces 
TGFβ-1 in the stromal cells, which further either stimulate stromal cells to 
release other factors, such as FGF-2, CTGF, BMP6, IL6, or induce the epithelial 
cells to undergo epithelial mesenchymal transition.  More comprehensive study 
will be focused on how the primed stromal cells change the cancer 
microenvironment.  
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CHAPTER V  
CONCLUSIONS 
 
Prostate cancer is the most common malignant neoplasm in men in the United 
States. Tens of thousands of men suffer from the disease without effective 
treatment. Even after initial therapy, the cancer recurs and becomes incurable. 
To tackle this epidemic disease, we sought out to focus on unraveling the 
mystery from two perspectives, prostate stem cells and the tumor 
microenvironment. 
A rare population of cells, prostate cancer stem cells (CSCs), may play a critical 
role in the development and progression of PCa. Given the similarity between 
normal stem cells and CSCs, it is hypothesized that prostate CSCs may 
originate from oncogenic transformation of normal prostate stem cells. Thus 
understanding normal prostate stem cells is essential for insight into prostate 
cancer stem cells. However, where prostate stem cells reside and how prostate 
stem cells are regulated still needs to be deciphered. In this study, we showed 
that P63-expressing prostate basal stem cells (P-bSCs) represents primitive 
stem cells. By interrogating FGF signaling in prostate stem cells, we found type 
II FGFR is crucial for prostate basal stem cell self-renewal. Disrupting FGFR2 
and its downstream signals promotes basal to luminal cell differentiation, thus 
impairs both basal cell homeostasis and prostate postnatal development. 
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Cancers are not just masses of malignant cells but a complex ecosystem in 
which many other cell type are recruited and altered. The tumor 
microenvironment is being increasingly recognized as a key factor in disease 
progression and distant metastasis. In our study, we discover that 
overexpression of FGF9 in prostate epithelial cells elicits high-grade PIN and 
invasive carcinoma. In addition, the neoplastic cells induce various changes to 
convert the adjacent stroma compartment into a pathological entity, i.e. reactive 
stroma.  
Overall, our study reveals how FGF signaling regulates the homeostasis of 
prostate basal stem cells. This is important because deregulation of the basal 
stem cells is a critical biological event during prostate cancer initiation and 
progression. We have also uncovered that FGF signaling is essential for the 
growth and survival of prostate cancer, due to its profound impact on the 
reciprocal cross-talk between epithelial cells and stromal cells.  
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